What Echocardiography Can Reliably Tell Us About Our Pulmonary Hypertension Patients
Natasha A. Vedage, MD; Anjali Vaidya, MD, FACC, FASE, FACP

Multimodality Imaging of Pulmonary Hypertension
Seth Kligerman, MD; Michael Horowitz, MD, PhD; Lewis Hahn, MD; Albert Hsiao, MD, PhD; Elizabeth Weihe, MD

The Future of Imaging in Pulmonary Hypertension: Better Assessment of Structure, Function, and Flow
Akhil Narang, MD; Benjamin H. Freed, MD

Pulmonary Hypertension Roundtable: The Present and Future of Imaging in Pulmonary Hypertension
Jeffrey D. Edelman, MD; Harrison W. Farber, MD; Benjamin H. Freed, MD; Paul Hassoun, MD; Peter Leary, MD, PhD; Sudhakar N.J. Pipavath, MD; Anjali Vaidya, MD, FACC, FASE, FACP

Ask the Expert: Radiographic Signs and Patterns of Pulmonary Hypertension: A Pictorial Essay
Hugo Carmona, MD; Wei Wu, MD; Sudhakar N.J. Pipavath, MD

PH Grand Rounds: When a Clot Is Not a Clot: An Unusual Cause of Progressively Worsening Dyspnea in a Previously Healthy Woman
Nicholas Fox, MD; Victor Test, MD; Vinod Jona, MD; Russell Harley, MD; Rahul G. Argula, MD

PH Professional Network: Facilitating and Improving Adherence: The Development of a Pulmonary Arterial Hypertension Self-Care Management Agreement
Jacqueline M. Brewer, AGPCNP-BC; Samuel A. Allen, DO, FCCP
The Scientific Leadership Council of the Pulmonary Hypertension Association

The scientific program of the Pulmonary Hypertension Association is guided by PHA’s Scientific Leadership Council. The Council includes the following health care professionals.

Ronald J. Oudiz, MD
Chair
Professor of Medicine
Director, Pulmonary Hypertension Program
LA Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, CA

Murali M. Chakinala, MD, FCCP
Co-Chair
Professor of Medicine
Northwestern University School of Medicine
Medical Director Lung Transplantation
Chicago, IL

Jeffrey P. Conboy, MD
Chair-Elect
Professor of Medicine
Director, Pulmonary Hypertension Center
University of Virginia
Charlottesville, VA

Jeffrey R. Fineman, MD
Associate Chair
Professor of Medicine
University of Pennsylvania School of Medicine
Philadelphia, PA

Robert F. Machado, MD
Co-Chair
Director, Pulmonary Hypertension Program
University of Miami
Miami, FL

Shelley D. Waalburg, MD
Associate Chair
Professor of Medicine
University of Colorado School of Medicine
Denver, CO

Anjali Vaidya, MD, FACC, FASE, FACP
Associate Chair
Director, Pulmonary Hypertension Center
University of California, San Francisco
San Francisco, CA

David B. Badesch, MD
Co-Chair
Professor of Medicine
Department of Cardiovascular Medicine
University of Texas Southwestern Medical Center
Dallas, TX

A. De Jesus Perez, MD, FACC, FAHA
Co-Chair
Professor of Medicine
University of Michigan
Ann Arbor, MI

Kerry L. Chung, MD
Chair-Elect
Professor of Medicine
Director, Pulmonary Hypertension Program
University of Texas Southwestern Medical Center
Dallas, TX

Lori Chinn, MD
Chair-Elect
Professor of Medicine
Director, Pulmonary Hypertension Program
University of Texas Southwestern Medical Center
Dallas, TX

The mission of Advances in Pulmonary Hypertension is to serve as the premiere forum for state-of-the-art information regarding diagnosis, pathophysiology, and treatment of pulmonary hypertension (PH). The 2018 Nice revision of the World Symposium on Pulmonary Hypertension (Simonneau G, Montani D, Celemajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53(1), DOI:10.1183/13993003.01913-2018) serves as a guide to categories of PH addressed in Advances in Pulmonary Hypertension. While focusing on Group 1 PH (PAH; pulmonary arterial hypertension), the other categories (Group 2, PH due to left heart disease; Group 3, PH due to lung diseases and/or hypoxia; Group 4, PH due to pulmonary artery obstructions; Group 5, PH with unclear and/or multifactorial mechanisms) are also addressed. This mission is achieved by a combined review articles, roundtable discussions with panels consisting of international experts in PH, and original contributions.

Objectives

• Provide up-to-date information regarding diagnosis, pathophysiology, and treatment of PH.
• Serve as a forum for presentation and discussion of important issues in the field, including new paradigms of disease understanding and investigational trial design.
CONTENTS

109 Editor’s Memo
Deborah Jo Levine, MD

109 Guest Editors’ Memo
Jeffrey D. Edelman, MD; Harrison W. Farber, MD

110 What Echocardiography Can Reliably Tell Us About Our Pulmonary Hypertension Patients
Natasha A. Vedage, MD; Anjali Vaidya, MD, FACC, FASE, FACP

115 Multimodality Imaging of Pulmonary Hypertension
Seth Kligerman, MD; Michael Horowitz, MD, PhD; Lewis Hahn, MD; Albert Hsiao, MD, PhD; Elizabeth Weihe, MD

126 The Future of Imaging in Pulmonary Hypertension: Better Assessment of Structure, Function, and Flow
Akhil Narang, MD; Benjamin H. Freed, MD

134 Pulmonary Hypertension Roundtable: The Present and Future of Imaging in Pulmonary Hypertension
Jeffrey D. Edelman, MD; Harrison W. Farber, MD; Benjamin H. Freed, MD; Paul Hassoun, MD; Peter Leary, MD, PhD; Sudhakar N.J. Pipavath, MD; Anjali Vaidya, MD, FACC, FASE, FACP

141 Ask the Expert: Radiographic Signs and Patterns of Pulmonary Hypertension: A Pictorial Essay
Hugo Carmona, MD; Wei Wu, MD; Sudhakar N.J. Pipavath, MD

152 PH Grand Rounds: When a Clot Is Not a Clot: An Unusual Cause of Progressively Worsening Dyspnea in a Previously Healthy Woman
Nicholas Fox, MD; Victor Test, MD; Vinod Jona, MD; Russell Harley, MD; Rahul G. Argula, MD

157 PH Professional Network: Facilitating and Improving Adherence: The Development of a Pulmonary Arterial Hypertension Self-Care Management Agreement
Jacqueline M. Brewer, AGPCNP-BC; Samuel A. Allen, DO, FCCP

Advances in Pulmonary Hypertension is available online at www.AdvancesinPH.org. This site offers enhanced capabilities including a dedicated DOI and cross-referencing potential, as well as other features valuable to practitioners, researchers, and educators. Registration is recommended to access all site features and benefits.

Benefits of Registration Include:

- A unique user profile that will allow you to manage your current subscriptions (including online access)
- The ability to create favorites lists down to the article level
- The ability to customize email alerts to receive specific notification about the topics you care most about
Welcome to a very special issue of Advances in Pulmonary Hypertension (PH). Drs Jeffrey D. Edelman and Harrison W. Farber have guest edited this unique issue of the journal which encompasses “all things imaging in PH.” It is the only full journal devoted to this topic and will be used as a reference in the PH world for years to come. One significant distinction between this issue and others is the inclusion of a multitude of leaders and experts from many fields: pulmonologists, cardiologists, radiologists, researchers, and echocardiographers. Drs Edelman and Farber have brought this multidisciplinary team together to bring us an exquisite all-encompassing knowledge base on this topic.

To begin the issue, Drs Natasha A. Vedage and Anjali Vaidya explore the role of echocardiography as a tool which will help not only to detect PH, but also to discriminate among the subgroups of PH when a patient is being evaluated. They discuss novel approaches using echocardiography that will help clinicians predict the hemodynamic profile of a patient as well as help define etiology and severity of PH.

Radiologists from the University of California at San Diego—Drs Seth Kligerman, Michael Horowitz, Lewis Hahn, Albert Hsiao, and Elizabeth Wei—elucidate how imaging techniques play such an integral role in the workup of a patient with PH. The collaboration between radiologists and clinicians is imperative when assessing the pulmonary and systemic vasculature, heart, lungs, and mediastinum in order to make the correct diagnosis and manage the patient with PH.

Drs Akhil Narang and Benjamin H. Freed then discuss how novel techniques and advancements in current imaging techniques have provided the opportunity to extend imaging’s role from diagnostics to enhancing risk stratification and providing additional phenotypic data that may alter therapeutic management.

In a special feature for our “Ask the Expert” section, Drs Hugo Carmona, Wei Wu, and Sudhakar N.J. Pipavath take us through a pictorial tour of imaging in PH. They consider radiographic signs in all types of imaging that can be used in identifying the etiology and severity of PH, presenting multiple examples of a variety of imaging features that can assist clinicians in distinguishing some of the clinical manifestations of PH.

In our PH Professional Network corner this month, Ms Jacqueline M. Brewer and Dr Samuel A. Allen discuss the importance of team-based care that includes the patients themselves and their family as well as their health-care team. This section discusses how vital communication with all parts of the team is for the patients in terms of medication adherence, quality of life, and overall morbidity and mortality.

And of course, to round out this issue, Drs Edelman and Farber led an exceptional group of experts in the world of imaging for PH. Drs Benjamin H. Freed, Paul Hassoun, Peter Leary, Sudhakar N.J. Pipavath, and Anjali Vaidya convened to update us on the variable uses, benefits, and advances in radiographical techniques and echocardiography to diagnose and manage patients with PH.

This outstanding issue of Advances is an invaluable resource for all of us in the field of pulmonary vascular disease. Congratulations to Drs Edelman and Farber, as well as all of the contributors, on an excellent issue.

Deborah Jo Levine, MD
Professor of Medicine, Pulmonary and Critical Care
Medical Director Lung Transplantation
Director of Pulmonary Hypertension
University of Texas Health Science Center
San Antonio
San Antonio, TX

Jeffrey D. Edelman, MD
Associate Professor of Medicine
Pulmonary and Critical Care Division
University of Washington
VA Puget Sound Health Care System
Seattle, WA

Harrison W. Farber, MD
Professor of Medicine
Tufts University School of Medicine
Boston, MA

Every day, pulmonary hypertension (PH) is becoming a more multidisciplinary field. The area of imaging reflects this diversity and richness of expertise. From the simple chest x-ray to the latest magnetic resonance imaging, the data available from the images themselves combined with interpretation and evaluation in association with the computational and neural processing capabilities of machines and their masters are truly astounding.

Routine imaging with or without clinical suspicion may reveal the presence of PH and provide insight into its underlying causes and associated conditions. Ongoing refinements and innovations may further define progression, response to therapy, and provide insight into disease prognosis and pathogenesis.

As the technology of medicine continues to explode, it is becoming even more tempting and convenient to read reports instead of viewing the actual studies. The experience is unfulfilling and uninformative—like looking at the notes of a song without hearing the music or reading a recipe without tasting the food. In this issue of Advances in Pulmonary Hypertension, we take advantage of the new digital format to provide a plethora of representative images selected, described, and interpreted by our esteemed authors. We explore the basic findings and nuances of PH imaging as interpreted through the eyes and minds of radiologists, cardiologists, and pulmonologists. We hope you take advantage of this technology and spend time viewing the images in order to enhance your understanding of this disease entity.

Jeffrey D. Edelman, MD
Associate Professor of Medicine
Pulmonary and Critical Care Division
University of Washington
VA Puget Sound Health Care System
Seattle, WA

Harrison W. Farber, MD
Professor of Medicine
Tufts University School of Medicine
Boston, MA
What Echocardiography Can Reliably Tell Us About Our Pulmonary Hypertension Patients

Natasha A. Vedage, MD  
Temple University Lewis Katz School of Medicine  
Philadelphia, PA

Anjali Vaidya, MD, FACC, FASE, FACP  
Co-Director, Pulmonary Hypertension, Right Heart Failure, and CTEPH Program  
Advanced Heart Failure and Cardiac Transplant  
Temple University Lewis Katz School of Medicine  
Philadelphia, PA

Pulmonary hypertension (PH) is a complex, multi-organ system disease that is broadly defined by an elevation in pulmonary artery pressures. There are key biologic differences in the pathophysiology among the different PH subgroups that warrant a targeted approach to clinical care of these patients. The complex geometry of and wide array of clinical tools to assess the right heart in PH add another layer of complexity in patient care. Echocardiography can be used as a powerful tool to discriminate among the subgroups of PH, a critical first step in evaluating a new case of PH. In this article, we will explore novel approaches using echocardiography that go beyond simply estimating pulmonary pressures and provide a readily accessible means of adding diagnostic and prognostic accuracy in the clinical setting.

BACKGROUND
At the first World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) was defined as mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg measured by right heart catheterization (RHC) at rest.1 At the sixth WSPH, which met in 2018, the aforementioned definition of PH was criticized for being too conservative and lacking specificity for identifying patients with pulmonary vascular disease (PVD) or precapillary PH.

In a systematic review of over 130 studies, Kovacs et al. showed that mPAP in the supine position at rest in healthy individuals was 14.0 ± 3.3 mm Hg and rarely exceeded 20 mm Hg.2 Therefore, the prior definition of PH (mPAP ≥ 25 mm Hg) was greater than 2 standard deviations higher than what is observed in healthy individuals and could miss patients with true PH. For this reason, the latest WSPH changed the definition of PH to ≥ 20 mm Hg. Another major limitation of the previous definition was its lack of ability to distinguish between patients with precapillary and postcapillary disease. For example, an elevated mPAP would identify both a patient with underlying chronic obstructive pulmonary disease who has evidence of PVD and a patient with PH due to heart failure with preserved left ventricular ejection fraction (LVEF), but we know that these patients have very different physiologic pathways at play and thus are managed quite differently from a PH perspective.

Finally, in the previous classification of PH subgroups, only Group 1 or pulmonary arterial hypertension (PAH) included pulmonary vascular resistance (PVR ≥ 3 Wood units [WU; mm Hg/L-min]) despite the fact that almost all subgroups can exhibit a precapillary phenotype characterized by an elevated PVR.

This led to the proposal by the sixth WSPH to include PVR ≥ 3 WU in the definition for all forms of precapillary PH.3 There are several important clinical implications for the changes proposed by the sixth WSPH. The lowering of the mPAP criterion to define PH could potentially increase the number of PH patients referred for PH evaluation. In order to respond to a larger volume of patients being referred for PH evaluation, there must be readily accessible and validated tools to initially assess patients with suspected PH. Further, while RHC remains the “gold standard” for diagnosis, it is not always a practical tool for immediate accessibility and repeated measurements which are necessary in managing PH over time and in response to therapy. For this reason, novel echocardiographic measures that recapitulate invasive hemodynamics and even predict outcomes in PH represent a powerful tool in a clinician’s arsenal. While we acknowledge that echocardiography can be technically difficult due to the unique shape and geometry of the right heart, we sought to highlight echocardiographic measurements that are easy to perform and can accurately phenotype PH subgroups. Recognizing that there are multiple clinical factors that contribute to a patient’s presentation and ultimate prognosis, this review will focus on how echocardiography can be used to comprehensively assess patients with PH.

ESTIMATING HEMODYNAMICS
PVD is defined by the presence of PVR > 3 WU and normal to low left heart filling pressures. While RHC is required to make the diagnosis of PVD, it has

Key Words—pulmonary hypertension, pulmonary arterial hypertension, echocardiography, hemodynamics, TAPSE, RV morphology
Correspondence: anjali.vaidya@tuhs.temple.edu
Disclosure: The authors have no conflicts of interest to disclose.
several noteworthy limitations. It is an invasive procedure with nontrivial risks to the patient, including complications related to bleeding, vascular, lung, or cardiac injury. In fact, a large prospective study across 54 centers in the United States, the REVEAL registry, observed that the average duration between symptom onset and diagnostic catheterization was 2.8 years in patients with World Health Organization (WHO) Group 1 PAH. Further, common technical errors observed with RHC are often amplified in patients with underlying cardiovascular disease and, hence, several subgroups of PH. Wide variations across the respiratory cycle lead to underestimated end-expiratory values, and enlarged and dilated distal pulmonary artery branches in PVD make it difficult to obtain a fully occluded pulmonary capillary wedge pressure (PCWP), which can overestimate PCWP. RHC is often reserved only for patients in whom PVD is suspected, leaving a large population of PH patients where hemodynamic profiles are unknown and potentially misclassified. For this reason, novel approaches using echocardiography have emerged as a noninvasive and readily accessible alternative to hemodynamic assessment by catheterization.

Benza et al. performed a comprehensive evaluation of 2635 patients with PAH and observed that those who were initiated on therapy within 6 months of diagnosis had significantly improved long-term survival. Therefore, accurate identification of elevated PVR by echocardiography could reduce time to diagnosis of PVD and, more importantly, time to initiation of lifesaving PH therapies. Doppler echocardiography (DE)-derived estimates of PVR, such as the ratio of peak tricuspid regurgitation velocity to right ventricular outflow velocity-time integral ($VTI_{RVOT}$) have shown excellent correlation with invasive PVR across several studies; however, this correlation was not observed in patients with PVR > 8 WU. Thus, patients with the most severe degree of PVD, and therefore the most clinically vulnerable and urgent, are excluded from accurate utility of this tool. Others have used DE to estimate variables included in the calculation of PVR such as pulmonary artery pressures and cardiac output; however, this approach is time intensive and less useful for clinical practice. Arkles et al. demonstrated that easily observable differences in the shape of the right ventricular outflow tract (RVOT) Doppler signal could rapidly and accurately distinguish between patients with or without elevated PVR. Specifically, the presence of “notching,” either mid-systolic or late systolic notioning, of the right ventricular (RV) Doppler envelope was strongly associated with a PVR > 3 WU (odds ratio = 29.4, 95% confidence interval [CI] = 9.9, 87.2; Figure 1).

Similarly, Opotowsky et al. explored several models incorporating readily measurable echocardiographic parameters to estimate PVR. The model (Equation 1) that correlated best with invasive PVR (correlation coefficient $r$ = 0.80) also exhibited excellent discriminatory power across a range of PVR values (area under curve [AUC] = 0.946 for PVR > 3 WU).

$$\text{PVR} = \left( \frac{\text{PASP}}{VTI_{RVOT}} \right) + 3 \text{ if notch present}$$

where PASP is pulmonary artery systolic pressure.

Further work done by Opotowsky et al. demonstrated that a simple prediction score based on a few easy-to-perform echocardiographic measurements (left atrial size, $E/e'$ transmitral and tissue Doppler, and RVOT Doppler notch or acceleration time) had a positive likelihood ratio of 2.4 and a negative likelihood ratio of 0. A score $> 2$ was highly suggestive of PVD, whereas a negative score, in the presence of normal RV function (tricuspid annular plane systolic excursion or TAPSE > 1.8 cm), ruled out an elevated PVR (Figure 2).

Some studies have suggested that there are measurable changes in the pulmonary vasculature that precede an elevation in PVR. Bhattacharya et al. defined pulmonary arterial compliance (PAC) as the ratio of $VTI_{RVOT}$ over PASP. In this particular study, 156 patients from the University of Penn-

---

Figure 1: Examples of the 3 distinct patterns appreciated in the flow velocity envelope obtained from pulsed-wave Doppler interrogation from the right ventricular outflow tract ($FVE_{RVOT}$). (1a) and (1b) show representative Doppler tracings without evidence of Doppler notching (no notch group); note the envelope may be (a) parabolic or (b) somewhat triangular in shape. (2a) and (2b) show examples in the mid-systolic notch group, characterized by a distinct notch or nadir in its mid portion, dividing the flow profile into 2 distinct peaks. (3a) and (3b) show Doppler tracings with a late systolic notch, characterized by transient notching on the terminal aspect of the Doppler signal without 2 distinct peaks. Arrows indicate the location of the notch in the Doppler signal. Reprinted with permission of the American Thoracic Society. Copyright © 2019 American Thoracic Society. Arkles JS, Opotowsky AR, Ojeda J, et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. *Am J Respir Crit Care Med.* 2011;183(2):268–276. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.
sylvania were included only if they had a preserved ejection fraction (HFpEF). By including patients without reduced LVEF, the investigators of the study were able to demonstrate that PAC, measured by VTIRVOT/PASP, can readily be used to lay supine. In normal right hearts, longitudinal shortening accounts for up to 80% of overall RV function. For this reason, systolic displacement of the tricuspid annulus toward the RV apex or TAPSE is frequently investigated as an echocardiographic surrogate of RV function. Compared to other echocardiographic measurements of RV function, TAPSE offers several advantages in that it is highly reproducible, independent of geometric assumptions, and does not require RV endocardial tracing which is prone to error and technical difficulty. In a prospective study of a heterogeneous population of PH, with approximately 75% in WHO Group 1, TAPSE < 1.8 cm was associated with a fourfold increased risk of death. Follow-up TAPSE measurements, and not baseline, after initiation of PAH therapy predicted survival in a cohort of PAH patients. Specifically, follow-up TAPSE

**RV Function**

**TAPSE:** The presence of RV dysfunction has been widely recognized as an independent predictor of poor outcomes in PH. In a study of 110 patients with PAH, 25% of patients who experienced an improvement in PVR after medical therapy continued to have worsening RV function and ultimately had the worst outcomes, suggesting that RV dysfunction may be specific for severe or refractory disease. Similar to RHC, cardiac magnetic resonance imaging, which is the "gold standard" imaging modality to assess RV function, is limited by cost, accessibility, and patient-related factors such as claustrophobia and inability to lay supine. In normal right hearts, longitudinal shortening accounts for up to 80% of overall RV function. For this reason, systolic displacement of the tricuspid annulus toward the RV apex or TAPSE is frequently investigated as an echocardiographic surrogate of RV function. Compared to other echocardiographic measurements of RV function, TAPSE offers several advantages in that it is highly reproducible, independent of geometric assumptions, and does not require RV endocardial tracing which is prone to error and technical difficulty. In a prospective study of a heterogeneous population of PH, with approximately 75% in WHO Group 1, TAPSE < 1.8 cm was associated with a fourfold increased risk of death. Follow-up TAPSE measurements, and not baseline, after initiation of PAH therapy predicted survival in a cohort of PAH patients. Specifically, follow-up TAPSE
≥ 2 cm was associated with a decrease in all-cause mortality (hazard ratio = 0.21, 95% CI = 0.08, 0.60) and improved WHO functional class and 6-minute walk distance.\(^1\)

Prior to a study published by Sivak et al., it was unclear how much right atrial function contributed to RV function. Because total RV function is largely due to longitudinal shortening, Sivak et al. hypothesized that the increased distance between RV base and apex that occurs during right atrial systole is an important contributor to overall RV function. They compared 37 patients with PAH to 35 healthy controls and showed that RA systolic function accounted for 51% of TAPSE compared to only 32% in controls.\(^1\) This has important clinical implications in that maintenance of sinus rhythm in PAH is essential for preserving RV function.

Several studies have highlighted the significance of nonlongitudinal shortening of the RV, particularly in the context of underlying cardiopulmonary disease. It was initially observed that TAPSE values were lower in cardiac surgery patients, but overall RV function appeared to be preserved. This led to a study by Vaidya et al., who compared RV contractile patterns in patients who underwent cardiac surgery with controls. They found that, in the surgical cohort, there was a dramatic decrease in longitudinal shortening, but overall RV function was normal due to a gain in transverse shortening.\(^2\) In this patient population, a lower value of TAPSE could be misleading; therefore, careful examination for special cases of RV contractile patterns, such as postcardiothoracic surgery patients, should be part of routine RV functional assessment.

**Limitations of PASP Estimation:** In a single-center prospective analysis of PH patients who underwent RHC and had DE performed 1 hour later, pulmonary artery pressures derived from DE differed significantly from those measured invasively (48% > ±10 mm Hg of the invasive measurement). In the case of underestimated measurements, the Doppler jet across the tricuspid valve was of poor quality, a significant limitation in DE. Approximately half of the cases that had overestimated PASP had overestimated right atrial pressures. Therefore, known physiologic variations in inferior vena cava collapsibility can cause variability in right atrial pressures and is also a source of error in PASP estimation. In patients with underlying lung disease, it is technically more difficult to obtain optimal window views of the tricuspid regurgitant jet, which leads to inaccurate estimation of PASP.\(^2\)

**CONCLUSIONS**

- Echocardiography allows clinicians to simultaneously investigate the interplay between pathologic remodeling of the pulmonary vasculature in PH and the right heart’s adaption to it, thus providing a powerful means for comprehensive assessment.
- Novel echocardiographic measures and scoring tools can enable clinicians to confidently predict a patient’s predominant hemodynamic profile across several subtypes and severity of PH.
- Careful echocardiography interpretation should be used in conjunction with RHC, including serially, in the context of disease progression and response to therapy.

**References**


Elevated pulmonary arterial pressures are the result of a spectrum of diseases that have been classified into 5 categories by the World Symposium on Pulmonary Hypertension. The finding of pulmonary hypertension (PH) is usually the first step in a multidisciplinary workup to diagnose the underlying cause, as different etiologies have different treatment algorithms and outcomes. Diagnostic imaging plays a key role in not only the initial evaluation of a patient with PH, but also to assess disease progression or treatment response.

In trying to discover the underlying cause of PH, the diagnostic radiologist often must act as a detective. While some findings, such as varying degrees of enlargement of the pulmonary trunk and remodeling of the right heart, are ubiquitous in patients with PH, it is often the more subtle findings that can help elucidate the cause. These findings may be isolated to the lung parenchyma or may involve the pulmonary or systemic vasculature, heart, or mediastinum. The purpose of this article is to review the various findings of PH on computed tomography (CT) and ventilation/perfusion (V/Q) scans that can help one to differentiate between the various etiologies.

ASSESS THE PULMONARY VASCULATURE

When evaluating the pulmonary vasculature, there are various findings suggestive of PH that are common between the various causes. These include pulmonary artery (PA) enlargement, PA-to-aorta ratio >1, and an increased segmental artery-to-bronchus ratio (Figure 1). While 3 cm is often used as a normal

Figure 1: Idiopathic pulmonary arterial hypertension (PAH) in a 35-year-old woman. (A) Axial maximum intensity projection (MIP) image shows a dramatically enlarged pulmonary artery (PA) measuring 4.6 cm. This is much larger in size than the adjacent ascending aorta (Ao). (B) Examination of the segmental PAs (black arrows) show that they are much larger in diameter compared to the adjacent segmental bronchi (white arrows) consistent with pulmonary hypertension (PH). (C) Axial MIP through the lower lobes shows relatively rapid tapering of the PAs as they extend toward the periphery of the lung (white arrows). Some of the vessels have a corkscrew appearance common in cases of severe PH (black arrows). (D) Axial image through the heart shows pronounced thickening of the right ventricular (RV) wall (white arrow) due to RV hypertrophy. There is flattening of the interventricular septum (black arrow) toward the left ventricle (LV) due to increased RV pressures. The right atrium (RA) is also larger than the left atrium (LA) due to PH.

Correspondence: skligerman@ucsd.edu
Disclosure: The authors have no relevant personal financial relationships to disclose.
cutoff value for PA size, it is by no means a diagnostic finding as studies have found no direct correlation between PA diameter and mean PA pressure.3 Multiple factors can affect PA size and include body mass index, systemic hypertension, diabetes, age, and underlying cardiovascular disease.4 Therefore, if the main PA measures >3 cm, one should also look at size of the segmental arteries and adjacent bronchi. While a segmental PA-to-bronchi ratio greater than 1:1 is weakly correlated with elevated PA pressures,3 the presence of both parameters has a high specificity for the diagnosis of PH.4 An alternative and often preferred method is to assess the diameters of the main PA and the aorta. A ratio >1 is commonly associated with PH.5,6

It is extremely important to recognize chronic thromboembolic PH (CTEPH) as a cause of PH since invasive treatments can be curative.7 While disease involving the central vasculature can be quite conspicuous (Figure 2), with large chronic clots layering in and sometimes obliterating the lumen of the main and lobar arteries, disease isolated to the peripheral vasculature can be quite subtle. Close inspection of the segmental and subsegmental pulmonary vasculature on pulmonary angiography CT scans can show abrupt occlusion of PAs with a “pouch” defect, luminal irregularities with eccentric wall thickening, abrupt caliber change (often due to recanalization), and webs or bands (Figure 3).8–10

Pulmonary arterial hypertension (PAH, Group 1) includes idiopathic PAH, heritable PAH, drug/toxin-induced PAH, and PAH associated with connective tissue disease, human immunodeficiency virus (HIV) infection, portal hypertension, congenital heart disease, and schistosomiasis.1 In severe longstanding PAH, in situ thrombus and calcified atherosclerosis along the walls of the PAs may develop due to extremely high pressures (Figure 4). Even among experts, these findings can be mistaken for CTEPH, and given the differences in treatment, this distinction is quite important. One method to distinguish is to evaluate the morphology of the more peripheral vessels. While both can give rise to “corkscrew” appearing vessels and/or peripheral pruning of the vasculature, in PAH the findings are diffuse (Figure 1), while in CTEPH there are often discrete areas of lobar, segmental, and subsegmental obliteration (Figure 2). V/Q scan or dual-energy CT angiography can often help differentiate. In PAH, one will see heterogeneous regional perfusion without mismatch on V/Q scan or occlusive filling defects on CT scan (Figure 4). In CTEPH, V/Q mismatches correspond to vascular territories, and
discrete occlusive lobar, segmental, and subsegmental filling defects can often be seen on CT (Figure 5). Another method of differentiation is the evaluation of the pulmonary parenchyma, as discussed below, which show distinct changes associated with the underlying pathophysiology.

Another less common mimic of CTEPH is a PA sarcoma. Differentiation between these two entities can be difficult, which is highlighted by the fact that most PA sarcomas are initially misinterpreted as intravascular thrombus. However, certain findings, if present, are suggestive of a sarcoma, including a soft tissue mass nearly filling and potentially expanding the lumen of the pulmonary trunk, left PA, or right PA with protrusion of the proximal end of this mass towards the right ventricular (RV) outflow tract (Figure 6). The ends of the soft tissue mass are often curvilinear. The mass can demonstrate enhancement on portal-venous phase of imaging. Positron emission tomography-CT and magnetic resonance imaging may need to be performed to differentiate in complex cases.

**EVALUATE THE HEART AND SYSTEMIC VASCULATURE**

In addition to remodeling the PAs, chronically elevated pulmonary pressures cause remodeling of the right heart. Findings such as RV hypertrophy (free wall thickness >4 mm), RV dilatation (>1:1 ratio between RV and left ventricle diameter on axial images), and flattening or leftward deviation of the interventricular septum are associated with increased pulmonary pressures (Figures 1 and 2). PH can lead to RV failure, which is often associated with dilation of the inferior vena cava with reflux of contrast into the hepatic veins (Figure 7). Prolonged hepatic congestion can lead to cirrhosis.

The presence of a dilated right heart (with or without hypertrophy) should always prompt a careful search for an undiagnosed intracardiac or extracardiac
shunt as the cause of PH (Figure 7). Evaluation of the cardiac valves, even on a study performed without cardiac electrocardiogram gating, should be performed. Mitral stenosis, which manifests as thickening and calcification of the valve leaflets with severe left atrial dilation, can lead to PH (Figure 8). The aorta and branch vessels should also be assessed for irregularities, such as areas of stenosis and aneurysmal dilation, that may signify an underlying vasculitis as the cause of the PH (Figure 9).

**ASSESS THE PARENCHYMA**

**Interlobular Septal Thickening**

Interlobular septal thickening is most often seen in PH due to left heart failure. Smooth septal thickening represents the increased interstitial congestion/edema of the pulmonary veins and lymphatics related to increased left atrial pressures (Figure 8). Ultimately, the passive backward transmission of increased left atrial filling pressures leads to the pulmonary vascular remodeling and right heart failure associated with PH. Irregular septal thickening can be seen along with reticulation with fibrosis, and nodular septal thickening can be seen with sarcoidosis and lymphangitic disease.\(^\text{15}\)

In the absence of left heart failure/enlargement, interlobular septal thickening associated with PAH is the hallmark of postcapillary congestion seen in patients with pulmonary veno-occlusive disease (PVOD). PVOD is characterized by intimal fibrosis, which leads to the occlusion and narrowing of pulmonary veins from the postcapillary level and beyond. As a consequence, the lymphatic channels within the interlobular septa dilate and become edematous, leading to the

---

**Figure 7:** 67-year-old woman presenting to the emergency department with shortness of breath. (A) 4-chamber image through the heart from a pulmonary embolism computed tomography angiography shows a dilated right heart and right lobe pulmonary artery (black arrow) consistent with pulmonary hypertension. A defect is present in the superolateral and posterior aspect of the interventricular septum consistent with a sinus venosus atrial septal defect (SV-ASD). Incidental note is made of a left-sided superior vena cava (LSVC). (B) Sagittal oblique image through the heart shows a dilated right atrium (RA) and reflux of contrast into a distended inferior vena cava (IVC) due to elevated right heart pressures. The right-sided superior vena cava (SVC) is mildly enlarged centrally. An SV-ASD (black arrow) is present along the inferior aspect of the SVC near its junction with the RA allowing for communication between the right heart and the left atrium (LA). The right inferior pulmonary vein (PV) drains into the LA. The right superior pulmonary vein (white arrows) anomalously drains into the SVC (white arrow) consistent with a partial anomalous pulmonary venous return. The 2 anomalies coexist in the majority of cases of a SV-ASD.

**Figure 8:** Longstanding mitral stenosis (MS) leading to pulmonary hypertension in a 70-year-old woman. (A) Axial computed tomography image shows a dilated main pulmonary artery (PA). There is diffuse ground glass opacity with septal thickening due to pulmonary edema. (B) Axial image through the heart shows a dilated left atrium with thickening of the mitral valve leaflets (white arrows). (C) Doppler image from an echocardiogram shows a high velocity jet flowing from the left atrium (LA) into the left ventricle (LV) through a severely stenotic mitral valve with a markedly reduced opening area (white arrow).

**Figure 9:** Axial computed tomography in a 20-year-old woman with Takayasu’s arteritis shows marked narrowing of the left pulmonary artery (white arrow) due to vasculitis. The right pulmonary artery was also narrowed. Circumferential thickening of the wall of the aorta (white arrowheads) helps make the diagnosis of a large vessel vasculitis.
smooth interlobular septal thickening classically seen on CT (Figure 10) and the septal thickening (Kerley B lines) seen on radiographs.\(^{16,17}\) In PVOD, smooth interlobular septal thickening is often associated with scattered ground glass opacities, pleural effusions, and mediastinal lymphadenopathy.\(^{16–18}\) V/Q scans are regarded as nonspecific for PVOD and can have a wide range of interpretations ranging from normal to findings of “high probability” with mismatched perfusion defects.\(^{16,19}\) Although the distinction between PCH and PVOD on imaging can be difficult, septal thickening and pleural effusions are less common in PCH.\(^{21}\) In PCH, they represent the capillary proliferation within the alveolar walls; however, in PVOD these nodules represent the looplike capillary engorgement seen secondary to pulmonary venous narrowing and stenosis.\(^{16}\) Given that PCH/PVOD share similar hemodynamic, clinical, and radiographic findings, revised guidelines recommend that PVOD and PCH be combined into a single diagnosis called “PAH with overt features of venous/capillaries (PVOD/PCH) involvement.”\(^{22}\)

**Nodules**

In an untreated patient with PAH, the presence of hazy centrilobular nodularity should raise the possibility for pulmonary capillary hemangiomatosis (PCH; Figure 11). These nodules are often diffuse in nature, involve all lobes, and spare the lung periphery.\(^{16,21}\) PVOD can be classified as idiopathic or associated to other conditions, including systemic sclerosis, HIV infection, pulmonary Langerhans histiocytosis, and sarcoidosis. PVOD is likely underestimated in sarcoid-associated PH (SAPH) and radiographically seen as smooth interlobular septal thickening with associated patchy areas of ground glass and/or venous infarcts.\(^{20}\) The pathophysiology of SAPH is complex and often multifactorial with 40% to 60% of patients with SAPH having no radiographic evidence of fibrosis.\(^{20}\)

In patients with PAH not related to PVOD/PCH, hazy ground glass centrilobular nodules can occur and can mimic findings seen in PCH (Figure 12).\(^{22}\)

While the nodules in PCH represent...
capillary proliferation in the alveolar walls, this finding in PAH has been attributed to periarteriolar cholesterol granulomas, large plexogenic arteriolar lesions, or small systemic collateral arteries. Distinction between the two can be difficult and may require biopsy. However, hazy centrilobular ground glass nodules are uncommon in other causes of PH.

Excipient lung disease is another rare cause of centrilobular nodules in the setting of PH. This is secondary to the intravenous injection of crushed oral tablets, usually narcotic pain killers. Excipients, including talc, microcrystalline cellulose, crospovidone, and starch, are insoluble inert filler materials that bind and protect the active drug. When the drug is injected, this material embolizes into the pulmonary arterioles, inciting a granulomatous reaction in and around the vessel. As the pulmonary arteriole is in the center of the pulmonary lobule, this granulomatous reaction leads to diffuse ground glass nodules which involve the entire lung from the apices to the bases. In comparison to the centrilobular nodules seen in PAH and PCH, these nodules tend to be small and well defined (Figure 13).

Sarcoidosis is a multisystem disease characterized by noncaseating granulomatous inflammation which often manifests along and within the pulmonary vessels and airways as well as the subpleural interstitium. This inflammation creates small nodules in a perilymphatic distribution which are distinct from the centrilobular nodules seen on PAH and PCH (Figure 14). As discussed below, symmetric mediastinal and hilar lymphadenopathy and perihilar conglomerate fibrotic masses may develop over time. Sarcoidosis may contribute to PH via capillary destruction and alveolar hypoxia/hypoxic pulmonary vasoconstriction in the setting of fibrosis in late-stage (class 4) disease; however, the degree of PH in these patients is out of proportion to the degree of fibrosis in many patients, implicating additional mechanisms of SAPH including pulmonary vascular infiltration/obliteration by granulomatous inflammation, altered flow dynamics due to lymphadenopathy, and cardiac/extracardiac disease.

Mosaicism
Specific patterns of a mosaic attenuation, defined as regional heterogeneity in pulmonary parenchymal attenuation, are characteristic for certain types of PH. Although any cause of PH can lead to a mosaic attenuation, PAH and CTEPH are the most common. Mosaic attenuation, also referred to as “mosaic perfusion,” reflects regional difference in lung perfusion in patients with PH.

In PAH, mosaicism often manifests as focal perivascular ground glass opacities, or small, scattered areas of increased attenuation often confined to center of the secondary pulmonary lobule (Figure 15). In some instances, the perivascular hyperattenuation can appear as subtle ground glass centrilobular nodules as discussed above.

Compared to the mosaic pattern seen in PAH, the pattern in CTEPH often manifests as larger, regional areas of decreased attenuation that correspond to a vascular territory with associated narrowing or occlusion of the supplying vessel (Figure 15). In severe cases of CTEPH, in addition to areas of hypoperfusion, segmental or subsegmental areas of hyperperfusion and increased attenuation can be present and reflect
shunting of blood to these nonoccluded regions. Within these areas of hyperperfusion, the corresponding vasculature is often engorged and increased in size compared to the adjacent bronchus reflecting increased blood flow (Figure 5).

PH due to left heart disease and PH due to lung disease and/or hypoxia are less likely to lead to a mosaic pattern. These can usually be distinguished on imaging by the presence of ancillary findings, for example, dilated left atrium in the setting of mitral valve disease, presence of severe emphysema, fibrosis, or other lung disease, as discussed below. Therefore, the combination of PA enlargement and mosaic attenuation should prompt a careful search for ancillary findings to help narrow the differential diagnosis.

**Emphysema**

The prevalence of PH in chronic obstructive pulmonary disease (COPD) varies from 50% in mild disease to 70% to 90% in severe disease. The pathogenesis of PH in emphysema is multifactorial, resulting from destruction of the pulmonary vascular bed, vascular remodeling, endothelial dysfunction, and thrombosis. The presence of PH is a poor prognostic indicator, and the 5-year survival rate was 36% for patients with a mean pulmonary arterial pressure >25 mm Hg in one series. Over time, PH in patients with emphysema can lead to cor pulmonale and subsequent right heart failure (Figure 16).

As emphysema is smoking related, findings are generally upper-lobe predominant. On CT, emphysema can be identified by abnormal lucency with a density less than -950 Hounsfield Units (HU), compared with a normal range -770 to -885 HU for lung parenchyma. The predominant finding of centrilobular emphysema is abnormal lucency in the central portion of secondary pulmonary lobules without a visible wall separating abnormal from normal lung parenchyma; the absence of a surrounding wall differentiates centrilobular emphysema from cystic lung disease. In severe disease, these spaces become extensive and confluent. Paraseptal emphysema typically involves the distal airways and is recognized by its involvement of the subpleural lung. Unlike centrilobular emphysema, the area of focal lucency may be surrounded by a thin wall. An area of paraseptal emphysema >1 cm is termed a bulla. Finally, in panlobular emphysema, there is uniform destruction of the pulmonary lobule; unlike other types of emphysema, panlobular emphysema tends to affect the entire lung uniformly or may be more basal predominant.

V/Q scintigraphy typically demonstrates in homogenous but matched upper lobe ventilation and perfusion...
corresponding to areas of emphysema.\textsuperscript{38} In some cases, a “stripe sign” may be seen, with centrally decreased perfusion and peripherally preserved perfusion, which is specific for centrilobular emphysema in COPD patients.\textsuperscript{39}

**Fibrosis**

Fibrosis is the common terminal stage in multiple interstitial lung diseases. Mechanisms of fibrosis related to growth factor release, fibroblast activation, and alterations to the endothelin system appear to be shared with the pathogenesis of PH.\textsuperscript{40} While nearly any fibrotic lung disease can be associated with PH, those most commonly associated with PH include collagen vascular disease (particularly systemic sclerosis and rheumatoid arthritis), idiopathic pulmonary fibrosis, and sarcoidosis.\textsuperscript{40}

On both chest x-ray and high-resolution CT, fibrosis usually presents as areas of peripheral reticulation with associated volume loss. More severe fibrosis results in pronounced architectural distortion and widening of the airways, known as traction bronchiectasis. Severe fibrosis also results in honeycombing, represented by multilayered 3 mm to 2 cm cysts in a subpleural location. Two specific histologic patterns of lung disease which demonstrate some of these findings are usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP).

A UIP pattern is seen in idiopathic pulmonary fibrosis (Figure 17) in addition to collagen vascular diseases, especially rheumatoid arthritis and scleroderma. This pattern is characterized by subpleural lower-lobe predominant peripheral reticulation, traction bronchiectasis, honeycombing, and extensive volume loss.\textsuperscript{41} NSIP, which is the most common pattern of fibrotic lung disease seen in patients with collagen vascular diseases, usually demonstrates symmetric lower-lobe predominant peribronchiolar ground glass opacity extending toward the periphery with associated reticulation and traction bronchiectasis.\textsuperscript{42} A characteristic feature of NSIP is the presence of subpleural sparing, distinguishing it from a UIP pattern (Figure 17). Differentiation between these two patterns can be difficult even for the most experienced radiologist.

Compared to the lower-lobe predominant fibrosis seen in UIP and NSIP, the fibrosis in sarcoid is usually perihilar and upper lobe predominant (Figure 18). Perilymphatic nodules may be visualized in areas adjacent to the fibrosis. Less common parenchymal findings include fibrocystic lesions, which manifest as irregular bronchiectatic and cystic changes with an upper lobe predominance. Pulmonary V/Q scintigraphy is usually noncontributory in these patients, and on occasion, vascular narrowing or occlusion due to surrounding lymphadenopathy or perihilar fibrosis can mimic findings in CTEPH (Figure 18).

**MEDIASTINUM**

Careful evaluation of the mediastinum is important in patients undergoing imaging workup for PH, as mediastinal abnormalities may implicate alternative, multifactorial diagnoses. Fibrosing mediastinitis (FM) is a rare but serious—and sometimes fatal—disease with focal granulomatous and diffuse non-granulomatous subtypes; diffuse disease is characterized by florid inflammation and fibrous proliferation within the mediastinum, which results in encasement and extrinsic compression of mediastinal structures including airways and vascular structures.\textsuperscript{43,45} Vascular manifestations most commonly involve the superior
tuberculosis infection, with rupture of the encapsulated granuloma thought to trigger an intense fibroinflammatory response in some patients, but diffuse disease can be secondary to myriad causes including trauma, prior radiation therapy, autoimmune disease (eg, rheumatoid arthritis and systemic lupus erythematosus), sarcoidosis, Behçet Disease, sclerosing neoplasm, or may be idiopathic.45

Classically, CT will demonstrate an infiltrative middle mediastinal soft tissue mass with encasement of adjacent structures (Figure 19). Pulmonary arterial abnormalities are typically central in distribution (ie, main, lobar, or segmental) with architectural distortion secondary to fibrosis, inducing irregular arterial narrowing and peripheral soft tissue thickening. Pulmonary venous involvement may be characterized by soft tissue encasement of central pulmonary veins, juxta-ostial or perivenous masslike tissue resulting in stenosis or occlusion, and can be quite dramatic with a pronounced, abrupt “shoulder.” Findings of pulmonary edema, including interlobular septal/peribronchial thickening and centriflobular ground-glass opacities, are common in these patients and, when due to PA or vein stenosis, may be geographic depending on the level of obstruction.44 Secondary pulmonary venous infarcts manifest like pulmonary infarcts associated with acute pulmonary embolism, as peripheral, wedge-shaped opacities that may demonstrate central clearing. Scarring secondary to chronic infarcts often demonstrates an atypical distribution with parenchymal bands and peripheral/subpleural reticulation.45 Other CT findings associated with FM include diffuse mediastinal fat stranding/inflammatory change, calcified mediastinal/hilar lymph nodes, and pleural and/or pericardial effusions.

FM can mimic both CTEPH and vasculitis. The geographic areas of perfusion abnormality seen in FM may mimic CTEPH on V/Q scintigraphy, yet this distinction is crucial. While peripheral lobar thrombus in CTEPH may demonstrate a similar appearance, the other characteristic CTEPH findings of weblike filling defects and segmental and subsegmental occlusions will be absent in FM. There is no adequate medical treatment for FM, and currently favored treatment modalities include endovascular angioplasty and/or stenting versus meticulous surgical dissection; however, attempted surgical dissection of the fibrotic rind seen in FM can be extremely difficult and is associated with high perioperative morbidity/mortality.45 If these patients are misdiagnosed as having CTEPH, attempted pulmonary thromboendarterectomy can have devastating consequences. Distinguishing FM from vasculitis is also important, and the presence of alternating tapering/diversion of vessels and/or extrapulmonary vascular structures are highly suggestive of a vasculitis.

Mediastinal involvement with sarcoidosis most typically manifests as relatively symmetric enlargement of hilar and mediastinal lymph nodes with or without concomitant pulmonary parenchymal findings depending on the stage of the disease (Figure 14). Hilar and mediastinal lymphadenopathy is also a common finding in PVOD and is secondary to lymphatic congestion and vascular transformation of the sinuses, intrasinusal hemorrhage, and lymphoid follicular hyperplasia.47 (Figure 10). However, PVOD and sarcoid can usually be distinguished from one another through associated parenchymal findings as discussed above.

Finally, specific attention should be given to the esophagus. As mentioned above, FM may result in esophageal compression and upstream dilation. Alternatively, a patulous/dilated esophagus may be seen in the setting of scleroderma, a rare multisystem autoimmune disease that includes PAH in approximately 13% of patients (Figure 12). Interestingly, while patients with PAH related to scleroderma typically have slightly lower mean pulmonary arterial pressure compared to patients with idiopathic PAH, they have higher morbidity/mortality, poorer response to therapy, and worse outcomes than patients with idiopathic PAH, though the pathophysiology and mechanisms underlying these differences have not been entirely elucidated.48

**CONCLUSION**

The diagnosis of PH should initiate a multidisciplinary workup to elucidate
an underlying cause. Imaging, especially CT, plays an integral part in the initial evaluation. Careful assessment of the pulmonary and systemic vasculature, heart, lungs, and mediastinum allows for one to piece together various clues and make the correct diagnosis, optimizing patient care.

References


INTRODUCTION
The standard imaging evaluation of patients with known or suspected pulmonary hypertension (PH) includes the measurement of pulmonary arterial systolic pressure and the assessment of right ventricular (RV) size and function. While this information is certainly critical for the management of these patients, it is the very minimum of what current imaging technology can provide. Today, imaging modalities such as echocardiography and magnetic resonance imaging (MRI) can probe the pulmonary vasculature and deconstruct RV movement in new and exciting ways, providing greater mechanistic insight into the pathophysiology of this disease and a better understanding of how current therapies work. This review will focus on novel imaging techniques in PH, which have the potential to fundamentally change how we care for these patients.

ECHOCARDIOGRAPHY
Mortality and morbidity of patients with PH is closely linked to the function and size of the RV. Accordingly, echocardiographic evaluation of patients with known or suspected PH centers on attempts to accurately understand the RV. The anterior location of the RV within the thorax coupled with its complex geometry make echocardiographic assessment particularly challenging. No single echocardiographic view adequately captures the entirety of the chamber, either anatomically or with respect to functional analysis. Moreover, the complicated contraction of the RV (longitudinal fiber shortening along the lateral tricuspid annulus towards the apex, free wall inward movement or “bellows effect,” and anteroposterior free wall shortening over the shared ventricular septum) have resulted in the development of multiple quantitative parameters.

General Echocardiographic Analysis
Conventional echocardiographic assessment of RV size and function incorporates a number of 1- and 2-dimensional (2D) indices. Size of the RV is often assessed using linear dimensions of the RV from a number of views including parasternal and apical views. RV function is often qualitatively evaluated, though this is subject to considerable inter- and intra-observer variability. Quantitative assessment of RV function can be accomplished through several different techniques, most commonly: tricuspid annular plane systolic excursion (TAPSE), S’ velocity, and fractional area change (FAC).

TAPSE (M-mode) reflects the basal to apical shortening or distance traveled of the lateral tricuspid valve annulus between end-diastole and end-systole while S’ (tissue Doppler imaging) measures the myocardial systolic excursion velocity at lateral tricuspid annulus. Both TAPSE and S’ primarily evaluate the longitudinal motion of the RV free wall while not incorporating the other aspects of RV contraction. Both of these parameters are also angle dependent and do not fully account for global RV function. RV FAC better reflects global RV function and relies upon accurate tracing of the RV end-diastolic area (EDA) and end-systolic area (ESA) where FAC = (EDA – ESA)/EDA.

Furthermore, beyond evaluation of RV systolic pressure and pulmonary artery (PA) pressures using Doppler echocardiography (through assessment of the RV-right atrial gradient or pulmonary regurgitation signal and modified Bernoulli equation), a complete noninvasive hemodynamic assessment is possible...
and should routinely be performed. These parameters include right atrial pressure, pulmonary vascular resistance, and evaluation of left-sided pressures. Furthermore, other echocardiographic parameters such as a reduced PA acceleration time (pulsed-wave Doppler) and notching of the right ventricular outflow tract Doppler tracing are markers of significant PH.4

While these conventional echocardiographic RV parameters are helpful in understanding downstream consequences of PH on the size and function of the RV, each have their shortcomings. In recent times, there is emerging data on the use of novel echocardiographic indices that, when coupled with conventional assessment, further enable the clinician to interrogate the sequelae of PH (Figure 1).

Three-Dimensional (3D) Echocardiography
The development and refinement of 3D echocardiography over the past several decades have allowed for tremendous progress in our understanding of the RV.5,6 Through the transthoracic acquisition of a pyramid of ultrasound data, there is now the capability to obtain accurate volumetric measurements of the RV, which much more closely reflect the “gold standard” of MRI.

Previous studies have confirmed 3D RV volumes measured by echocardiography better correlate with MRI measured volumes than 2D RV echocardiography volumes.7–9 Accordingly, the calculation of 3D RV ejection fraction (EF) derived from 3D volumes represents another important index to evaluate RV size and function. 3D RVEF is the only parameter that fully incorporates global RV function throughout the cardiac cycle. Serial interrogation of 3D RV volumes and EF in response to therapies for PH (including diuretics) may yield import-
ant data that reflect RV remodeling over time. Adequate interpretation and analysis of 3D volume acquisitions of the RV depends on user experience and training and is often a barrier to widespread adaptation. The advent of artificial intelligence and machine learning may allow for greater incorporation of 3D echocardiography. Once 3D images are acquired, automated postprocessing analysis generates RV volumes and EF that are comparable to MRI assessment.

**RV Shape**
Remodeling of the RV in PH is also best understood using 3D echocardiography. 3D RV full-volume acquisitions can be segmented into endocardial surfaces from which RV shape can be determined. Parameters from these surface maps, namely curvature, are then quantifiable. In patients with PH, the RV septum is convex in curvature and bulges toward the left ventricle throughout the cardiac cycle unlike in normal subjects. Additionally, in PH (unlike healthy controls), the RV free wall and apex demonstrate convexity throughout the cardiac cycle.11-13 Temporal changes in these differential, regional curvature changes during the course of therapy may be a useful means of monitoring disease progression or regression.

**Tricuspid Regurgitation**
In patients with progressive PH, functional tricuspid regurgitation often results as a consequence of RV and tricuspid annular remodeling. The progression of tricuspid regurgitation in PH has been shown to be associated with progressive increasing all-cause mortality. From an echocardiographic standpoint, progressive tricuspid regurgitation has been associated with higher PA pressures, increasing RV enlargement, worsening RV sphericity, tricuspid annular dilation, and increasing tricuspid valve tenting area. Patients who experience worsening tricuspid regurgitation in serial imaging warrant special attention as this may suggest worse outcomes.14

**RV Strain**
Myocardial deformation analysis is the underlying principle of strain. Speckle-tracking echocardiography (STE) is the predominant method by which strain is calculated. STE relies on tracking motion of ultrasound speckles throughout the cardiac cycle. The speckles are created as a result of ultrasound beam scatter and can be identified by frame by frame as they move across systole and diastole. Tracking these speckles allows for the creation of strain and strain rate curves. STE relies on imaging at high frame rates, typically >50 frames/second. There are a number of benefits of strain imaging, namely that measurements generally reflect global function (accounting for abnormalities that occur throughout the cardiac cycle), and strain is angle- and mostly load-independent.15

Unlike the left ventricle, where longitudinal, circumferential, and radial strain are all useful parameters of myocardial deformation, the longitudinal strain of the RV best reflects the underlying myocardial fiber architecture of the RV. Furthermore, due to the shared septum between the right and left ventricles, the septal contribution to RV strain is typically ignored in favor of using the longitudinal strain of the RV free wall.

In patients with seemingly normal parameters of RV function, abnormalities in RV free wall longitudinal strain often reflect subclinical RV dysfunction before it may be readily apparent or measured by 1 or 2D echocardiographic parameters. Similarly, the RV free wall can be subdivided into the basal, mid, and apical segments. Regional RV remodeling in PH, in addition to other pathologies, can also be detected by regional strain changes.

In PH, abnormal RV free wall strain has been associated with worse outcomes and New York Heart Association functional class. The cutoff values for RV strain in PH vary from study to study, but improvements in strain are generally observed in response to medical therapy.16-19 Worsening RV strain despite medical therapy should be seen as a sign of possible RV failure.

**Impact on the Left Ventricle**
While PH is primarily thought of as a disease of the right heart, its impact on the left ventricle has recently become clearer. Generally the left ventricular (LV) EF is preserved in PH, so when significant reduction in LVEF occurs, the prognosis is often dismal. However, when the LVEF is normal, newer work has shown LV global longitudinal strain is independently associated with death in addition to right-sided heart abnormalities.19 In addition to routine assessment of RV strain, consideration should be given to following LV strain as well.

**MRI**
The role for MRI in the evaluation of patients with PH is rapidly evolving. MRI is already considered the “gold standard” for assessment of RV volume, mass, and EF, and the prognostic utility of all of these measures in PH is well established.20 In addition, MRI measurements of the pulmonary vasculature, including PA velocity, flow, and stiffness, have provided insights into the pathophysiology of PH and all show promise in the clinical workup of patients with this disease.20-22 This review will highlight newer MRI techniques such as RV strain imaging, RV T1 mapping, and 4-dimensional (4D) flow of the pulmonary vasculature that move beyond standard cine and 2D phase contrast imaging. The use of exercise MRI and deep learning will also be discussed.

**RV Strain Imaging**
As mentioned earlier, strain imaging measures myocardial deformation and is potentially a more sensitive metric of cardiac function than EF. RV strain is a strong predictor of outcomes in PH and adds incremental prognostic value to PA systolic pressure and other clinical variables.16,21,22 Given its ability to provide volumetric coverage of the whole heart, MRI is uniquely positioned to evaluate RV strain in a number of cardiac conditions including PH.

One of the first publications to evaluate RV strain in PH showed reduced longitudinal strain in several RV segments despite normal RVEF, highlighting the superior sensitivity of RV strain to detect regional changes in function.23 This study used strain encoded imaging which requires dedicated image acquisitions.

More recently, feature-tracking strain, which can be performed retro-
respectively using standard cine images, has shown promise in measuring RV strain (Figure 2, see also Supplemental Clips 1 and 2). In a study evaluating over 100 patients referred to MRI for PH evaluation, feature-tracking RV strain was feasible in 95% of patients and showed significantly reduced global circumferential strain rate in patients with normal RVEF. Furthermore, RV strain was independently associated with the composite endpoint of death, lung transplantation, or functional class deterioration.

Tello et al. used pressure-volume loop measurements to help determine which RV indices are most associated with strain. In a study of 38 patients with PH who underwent conductance catheterization within 24 hours of feature-tracking RV strain, long-axis RV radial strain was associated with RV-PA coupling while RV longitudinal strain showed a significant association with RV end-diastolic stiffness.

**RV T1 Mapping**

One of the most unique capabilities of MRI is characterizing tissue abnormalities using gadolinium contrast. In PH, late gadolinium enhancement is frequently detected in the RV insertion points, likely due to RV remodeling. While commonly observed in this patient population, RV insertion point enhancement is rather nonspecific and is not independently associated with poor outcomes. Recent work has focused on RV T1 mapping, a technique that allows for quantitative measurement of diffuse interstitial fibrosis in the RV. Several PH studies show a significant association between RV insertion point T1 time (a measure of myocardial fibrosis) and LV eccentricity or interventricular septal angle, measures of RV remodeling. Similar to previous papers evaluating RV insertion point late gadolinium enhancement, Saunders et al. found no relationship between RV insertion point T1 time and outcomes. Kawel-Boehm et al. examined T1 mapping of the RV free wall using standard modified look-locker inversion (an MRI sequence used for detecting myocardial fibrosis; MOLLI) recovery in 20 healthy controls. The authors found that the average T1 time of the RV free wall was significantly longer than the left ventricle. The authors believed this was due to the naturally higher collagen content in the RV, but volume averaging is also suspected. RV free wall T1 mapping was also evaluated in a recent study examining invasive pressure-volume loop measures in 42 patients with PH. The authors found that RV free wall T1 time (when averaged with RV insertion point and interventricular septum T1 times) correlated significantly with end-diastolic stiffness but not RV-PA coupling.

Higher resolution T1 mapping sequences, which may be more appropriate for the thin-walled RV myocardium, have also been studied (Figure 3). Recently, an accelerated and respiratory navigator-gated look-locker imaging sequence (ANGIE) was developed for T1 quantification of the RV. This technique provides higher spatial resolution for the thin-walled RV by using a segmented readout rather than a single-shot readout. The authors found that by using a midventricular short-axis slice during end systole at 1.5T, ANGIE provided similar RV T1 values to typical LV measurements in 9 healthy volunteers. In PH patients, ANGIE showed significantly increased RV diffuse fibrosis compared to subjects without PH, and this fibrosis was independently associated with PH even after adjustment for RV dilation and dysfunction.
PA 4D Flow Imaging

In conjunction with the development of novel MRI sequences to better understand the pathophysiology of the RV in PH, studies are also exploring additional methods such as 4D flow imaging to evaluate the pulmonary vasculature in this disease (Figure 4, see also Supplemental Clip 3). 4D flow MRI (time-resolved 3D phase-contrast MRI with 3-directional velocity encoding) offers the opportunity to noninvasively measure complex 3D hemodynamic changes with full volumetric coverage of the RV and PAs. This technique provides both qualitative assessment of altered blood flow (such as helix and vortex formation) as well as quantitative hemodynamic measures such as wall shear stress, pulse wave velocity, and vorticity.

Using 4D flow MRI in the pulmonary circulation, Reiter et al. observed abnormal vortex development in the main PA in patients with both resting and exercise-induced pulmonary arterial hypertension (PAH). Notably, the time persistence of this vortex correlated with the degree of PH as measured by mean PA pressure. Barker et al. extended this finding by reporting a significant decrease in peak systolic velocity, peak flow, stroke volume, and wall shear stress in the main PA and both PA branches in patients with PAH compared to controls. 4D flow imaging may also provide noninvasive assessment of more traditional hemodynamics. In PH patients with varying degrees of pulmonary vascular resistance by right heart catheterization, a multivariate regression equation that includes peak systolic vorticity, cardiac output, and relative area change in the main PA accurately estimated pulmonary vascular resistance across severe PH and normotensive populations.

Exercise MRI

Recent progress in MRI-compatible exercise equipment makes it possible to evaluate the above novel sequences during stress conditions. Recreating the hemodynamic changes associated with exertion inside the MRI scanner provides unique insight into the pathophysiologic alterations within the RV and pulmonary vasculature that may permit earlier detection of the disease.

Several studies have focused on RV contractility during exercise and the ability of the RV to maintain an appropriate cardiac output despite increasing afterload. Using RVEF as a surrogate of RV contractile reserve, Jaijee et al. showed a decrease in RVEF with submaximal exercise in chronic PAH patients despite normal RV function at rest. A separate study confirmed these findings and also showed that RV-PA coupling, as measured by stroke volume/end-systolic volume, was equally impaired with exercise in a small sample of patients with severe PAH. In both studies, the key driver of poor RV contractility in patients with PAH was the inability to augment RV end-systolic volume during exercise.

In addition to standard cine images for measuring RVEF and volume, 2D-phase contrast imaging has been used to evaluate changes in PA stiffness during stress. In patients with PH, stiffness of the main PA was shown to sig-
nificantly increase during exercise when measured by pulse wave velocity. This change significantly correlated with the stiffness index, β, as measured by right heart catheterization. A recent study also evaluated the value and reproducibility of feature-tracking RV strain in PAH patients during exercise MRI. Similar to previous studies showing a decline in RVEF during stress, Lin et al. showed a significant impairment in RV longitudinal strain with exercise with minimal inter-observer variability. Changes in RV strain during exercise might be a more sensitive marker for RV contractility than changes in RVEF.

**Deep Learning**

The use of artificial intelligence for cardiovascular imaging is rapidly gaining momentum. There are currently several studies evaluating deep learning approaches for assessing cardiac chamber volume, mass, and EF. These automated methods are particularly useful for MRI where manual biventricular segmentation is time-consuming and prone to errors. One recent study highlighted the benefit of adding anatomical shape prior knowledge to a 3D neural network–based segmentation method to specifically analyze biventricular size and function in patients with PH. These refinements to existing deep learning approaches will likely be of significant value in future PH clinical trials.

---

**Figure 4:** 4-dimensional flow right heart and pulmonary arteries. Altered blood flow in a patient with pulmonary hypertension as measured by vorticity. Note the vortex in the right atrium and main pulmonary artery indicating altered blood flow (yellow arrows). Image courtesy of Mohammed Elbaz, PhD.
COMPUTED TOMOGRAPHY (CT) AND POSITRON EMISSION TOMOGRAPHY (PET)

Both CT and PET play a limited but potentially useful role in the evaluation of PH. Noncontrast CT is frequently used to evaluate the lung parenchyma and is necessary to diagnose PH due to lung disease. Noncontrast CT may also provide diagnostic clues for rare types of PH such as pulmonary veno-occlusive disease or pulmonary capillary heman-giomatosis. Dual-energy CT is a newer method that provides both functional and anatomical data of the pulmonary vasculature. This method has been tested in patients with chronic thromboembolic PH and has performed well in generating quantitative lung perfusion and angiography using a single acquisition. PET provides unique metabolic information in patients with PH, but its clinical role, due in part to cost, radiation, and lack of accessibility, has yet to be established. Several studies have shown increased myocardial and lung glucose utilization in patients with PH using 18F-fluorodeoxyglucose (FDG). The degree of FDG uptake significantly correlates with measures of RV dysfunction. FDG uptake also appears to predict outcomes in patients with PH and may be useful in tracking therapeutic efficacy.

CONCLUSION

As therapies continue to evolve for PH, emerging noninvasive imaging techniques will be crucial for the accurate assessment of cardiac structure, function, and blood flow. Noninvasive imaging modalities also offer tremendous potential as research tools to enhance our understanding of the pathophysiology of PH. Interdisciplinary teams including cardiologists, radiologists, and pulmonologists should jointly be involved in the selection of one or more imaging tools to best manage these patients. Future PH studies should focus on the effectiveness of applying a value-based imaging approach centered on quality, safety, and cost.

References

27. Freed BH, Gomberg-Maitland M, Chandra S, et al. Late gadolinium enhancement cardiovas-
The Present and Future of Imaging in Pulmonary Hypertension

This fall, Guest Editors Jeffrey D. Edelman, MD, Associate Professor of Medicine at the University of Washington in Seattle, and Harrison W. Farber, MD, Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts, convened a panel of experts to discuss the role of imaging in pulmonary hypertension. Guests included Benjamin H. Freed, MD, Assistant Professor of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Illinois; Paul Hassoun, MD, Director of the Pulmonary Hypertension Program and Professor of Medicine at Johns Hopkins University Department of Medicine in Baltimore, Maryland; Peter Leary, MD, PhD, Associate Professor of Medicine and Director of the Pulmonary Vascular Disease Program at the University of Washington in Seattle; Sudhakar N.J. Pipavath, MD, Professor of Cardiothoracic Imaging and Adjunct Professor of Pulmonary, Critical Care, Sleep Medicine and Medicine at the University of Washington in Seattle; and Anjali Vaidya, MD, FACC, FASE, FACP, Associate Professor of Medicine and Co-Director, Pulmonary Hypertension, Right Heart Failure and CTEPH Program at Temple University in Philadelphia, Pennsylvania.

Dr Edelman: Good afternoon, everyone. Thanks for joining us. This is the roundtable for Advances in Pulmonary Hypertension Volume 18 issue 4, focusing on imaging in pulmonary hypertension (PH). I am Jeff Edelman, a pulmonologist at the University of Washington, and my co-moderator is Harrison Farber, a pulmonologist at Tufts University. Before we start, I was hoping we could go around and identify ourselves and our disciplines and where we are.

Dr Pipavath: Yes, I’m Sudhakar Pipavath, chest radiologist at the University of Washington, Seattle.

Dr Hassoun: Hi, this is Paul Hassoun, a pulmonologist at Johns Hopkins in Baltimore.

Dr Vaidya: This is Anjali Vaidya. I’m a cardiologist at Temple University.

Dr Leary: This is Peter Leary. I’m a pulmonologist at the University of Washington.

Dr Freed: I’m Ben Freed. I’m a cardiologist at Northwestern in Chicago.

Dr Edelman: Okay, excellent. Thank you. I’d like to start with the general comment that our imaging studies can play dual roles of identifying and finding patients with evidence of PH as well as in the evaluation of PH, such as assessing the severity and identifying associated conditions. There is fundamental information that’s assessed and identified on most studies in routine clinical settings, while more detailed data and evaluation can be obtained in more specialized settings. I think that experts from different fields, as we have in this group, bring different skillsets and perspectives to the table, and our overall evaluation is really enhanced by this multidisciplinary approach.

I hope our discussion today is going to reflect this diversity. I’m not sure where we’re going to go in the next hour. I do have some basic starting points, but I think we’ll let the discussion move from there. As a basic starting point, I think it’s worthwhile to mention and discuss what imaging modalities we think are routine in evaluating patients with known or suspected PH.

Dr Pipavath: I look at imaging (radiology) of PH being useful in three areas. Number one is diagnosis of PH, be it early, or when there are clinical symptoms and signs. In this situation, one tends to employ an additional investigation and then try to make a diagnosis. The second area is to determine the cause of PH that we can figure out at imaging. There are various causes of PH that imaging can help identify. The third area is imaging as guidance for treatment in some conditions. We have not fully explored the ability of standard imaging in quantification, specifically assessment of severity of PH. I don’t think the standard imaging modalities are that great in terms of quantification. Standard radiology imaging signs have certain predictive values for the diagnosis of PH. However, none of these are predictive enough to cross the treatment threshold for you to start treating PH on the basis of imaging signs alone.

You might employ an invasive study such as the right heart catheterization, which is considered the “gold standard.” In practice, you may not be able to perform this test in everyone—this is my understanding, you all need to correct me if that’s not the case—and that leads to the next best confirmatory test, the echocardiogram, where you are looking for a tricuspid regurgitation jet, I suppose. I’m sure the cardiologists will be able to say the most about its diagnostic value.

Dr Edelman: For the patient with symptoms that lead you to suspect PH, I think the basic imaging studies that we’re going to start with are going to be chest x-ray, computed tomography (CT), echocardiogram, and ventilation-perfusion (V/Q) scan. There are some fundamental findings there that are going to further lead us down the PH pathway or perhaps identify some other cause of dyspnea. I think those are our basic workhorse studies. . . yes?

Dr Vaidya: I agree. I would just add, I think the question was along the lines of the routine imaging that’s available
and used, and I think of it as echocardiogram, V/Q scan, and CT angiogram. Chest x-ray is important and can be helpful, but unfortunately, it’s not utilized adequately to raise the suspicion diagnosis often enough. While we want to talk about it and teach about it, it’s routinely not interpreted as abnormal in PH. The echocardiogram, of course, for basic awareness for PH, and then it has two additional utilities. One is to recognize the likelihood of the underlying hemodynamic profile that can then be confirmed by catheterization. The other utility is to use it as a guide once we’re down the road of PH medical management to see if we’ve achieved treatment goals. Then the V/Q scan to make chronic thromboembolic PH (CTEPH) diagnosis, and then the CT is equally important to assess for underlying parenchymal lung disease, or if we’re going to go down the road of CTEPH evaluations at Temple, to include the CT angiography. Those are my three.

Dr Hassoun: Are we talking about all imaging or just heart imaging? I’m a little bit confused there. Are we talking about all imaging in PH?

Dr Edelman: All imaging.

Dr Hassoun: I see. Okay.

Dr Freed: I would add to the discussion. I think that we also have to think about the judicious use of all these imaging modalities because we have a lot of them. We have CT and V/Q and chest x-rays and echocardiograms. We have to figure out a better way than sort of the shotgun approach to providing the information that’s needed.

I think one of the big strengths of echocardiogram is that you can use it to not only identify PH, but to also help further refine where the PH might be coming from. There are many signs on echocardiogram that can help you differentiate between pulmonary arterial hypertension (PAH) or pulmonary venous hypertension. I think that can really help you figure out what potential other imaging modalities you might need, if anything else, before you go ahead and order all these other tests for the workup.

Dr Farber: Let me take that thought one step further. There’s a paper from 3 or 4 years ago in which the authors, who were not clinicians, but just medical economists, looked at the workup for PH strictly from a monetary standpoint. They concluded that, on a cost-benefit ratio, the most cost-effective way to proceed if you think somebody has PH is, first, get an echocardiogram. If it’s abnormal, proceed directly to right heart catheterization, and then do the rest of the workup if they have PAH because, with the prevalence of diastolic heart disease, you’re going to do a lot of imaging or a lot of workup before you actually catheterize somebody who doesn’t have the disease you’re looking for.

Dr Vaidya: I completely agree. Either the echocardiogram has to strongly suggest a pulmonary vascular resistance (PVR) problem, or the right heart catheterization has to confirm a PVR problem before going down the full road of V/Q and CT of the chest.

Dr Edelman: There are nuances in both of those comments because I think Hap said, “if the echocardiogram suggests PAH,” and then Anjali said, “specifically a PVR issue.” If you were to take that further, the echocardiogram might be a stopping point, either if it was completely normal or if it suggested a left-sided cardiac problem. Am I interpreting those two comments correctly?

Dr Vaidya: Yes.

Dr Pipavath: The question that I have is, how often can you clinically suspect PH? Are there symptoms or clinical signs? Do they help you in any way, or are you mostly doing a study to assess the cause of shortness of breath, dyspnea, or dyspnea on exertion? Then you go through a series of investigations like just radiographs, CT, or echocardiogram. Then you arrive at the diagnosis of PH and then go downstream in terms of becoming more granular in workup?

Dr Vaidya: I think it can happen in a variety of ways. Both of those scenarios you described are quite common. There are going to be multiple providers out there that are just simply working up dyspnea and ordering a host of imaging tests to work it up and then ultimately land on PH. Probably those of us in this conversation are accustomed to recognizing specific symptoms, things like exertion on presyncope, syncope, exertional angina, physical exam findings that are very obvious to us for right heart congestion, the right heart abnormalities. We may go down that route in a more focused way earlier, but I think it can happen either way.

Dr Farber: Also, nowadays, realistically, people who are short of breath usually get an echocardiogram fairly early and/or a chest x-ray. If the chest x-ray is at all suggestive, you get an echocardiogram. If that is abnormal, go directly to catheterization.

Dr Pipavath: This might be a stupid question, but whenever you do an echocardiogram, do you always look for the pulmonary artery pressures?

Dr Farber: Sure. However, I am more interested in what the right ventricle looks like. The only question with the echocardiogram is, do you do tricuspid annular plane systolic excursions (TAPSE) on everybody, right ventricular outflow tract (RVOT), pulmonary artery acceleration time, etc.? The cardiologists can play with that.

Dr Pipavath: What is the sensitivity of echocardiogram? Does it pick up all cases of PAH?

Dr Farber: The false-positive rate was said to be 30% to 40%. That may be a little better now. The false-negative rate is unknown; it’s thought to be very low, but nobody actually knows the number because you don’t catheterize a whole bunch of people with normal echocardiograms.

Dr Leary: I would like to double back on the false-negative rate of echocardiography. There is a tendency to focus just on the estimates of right ventricular (RV) systolic pressure on the echocardiogram, but when you narrow in on the pressure, you lose a lot of the richness in
the echocardiogram in order to inform the diagnosis. Once you take into account RV dilation, RV dysfunction, and notching of the RV outflow tract Doppler envelope, then even if the RV systolic pressure does not suggest that you have PH, the sensitivity of echocardiogram to pick up meaningful pulmonary vascular disease goes up. When you rely on just pressures alone, you are certainly going to miss some people.

Dr Freed: I couldn’t agree more. It’s not just about the pulmonary arterial pressure, which we do get on all patients, but you’re also looking for septal flattening, RV function, and then some of the things I mentioned in terms of trying to differentiate between left-sided causes of PH versus more a precapillary process. Echocardiogram is very rich, if you use it properly, in providing a lot of information that can really help your diagnosis and determining whether or not this patient truly has PH.

Dr Vaidya: You could go so far as to say that the RV systolic pressure estimation or the pulmonary artery systolic pressure estimation is the least helpful part of an echocardiogram outside of the initial screening and recognition that there’s an underlying problem. Everything else is so much more useful in terms of the left atrial size, the E/e’ ratio, the systolic septal flattening, or the pulse wave Doppler in the RVOT, as well as the RV size and function. When you put all that together, I completely agree with what was said, that it is very rich and full of information. The pressure estimation alone has the least utility.

Dr Pipavath: Would you say then that there is no requirement for right heart catheterization because false negativity is pretty close to zero? I’m obviously asking a leading question.

Dr Vaidya: No. I don’t think you can say that there is no role for the right heart catheterization; there will also be too many users without adequate expertise making mistakes on this basis. The utility is to recognize early on what the likely underlying hemodynamic profile is and then move quickly to confirm that and move quickly to do the subsequent testing, like Hap said earlier. Get the V/Q. Get the additional chest imaging if it’s suggestive of that. Move more quickly to the right heart catheterization when you have features that suggest an underlying PVR problem versus maybe looking more closely for risk factors for left heart congestion when you have the other appearance on the echocardiogram, but the catheterization should still be done. It should be done with a little more insight.

Dr Edelman: In the sixth World Symposium consensus proceedings section addressing PH due to left heart disease, there’s actually a nice table that combines echocardiogram and other clinical findings to characterize the pretest probability of left heart disease phenotype. So using echocardiogram findings and other clinical data, one can define scenarios where maybe all you need is the echocardiogram to say there’s probably not PH here, or there is PH, but it is very likely due to a left-sided etiology. I think that combination of study findings with clinical suspicion is certainly important in guiding decisions as well.

Dr Leary: I think that it was important how you framed this as a negative, Jeff, and I agree. Echocardiogram is relatively good at excluding a diagnosis of PAH either by arguing against PH altogether or by arguing for left heart disease as the explanation for PH. On the other hand, even if an echocardiogram looks like PAH, it is not adequate to confirm a diagnosis of PAH. Even if you don’t see clear evidence of left ventricular systolic dysfunction or valvular cardiomyopathy, if you’re playing the numbers, it is still probably more likely to represent heart failure with preserved ejection fraction than PAH. For me, this is still the key reason why right heart catheterization really can’t leave our algorithm. If we neglected the heart catheterization, we would likely be mistreating a phenomenal number of people who really have diastolic dysfunction that was difficult to appreciate or misinterpreted on the echocardiogram.

Dr Edelman: I agree with that, Peter. I guess I was framing it in the setting where you may have enough information to determine that there is a likely PH etiology, such as left-sided heart disease, for which you might proceed to treatment without right heart catheterization. I wasn’t saying that, if you suspect that there’s PAH, the echocardiogram is good enough, but that there are settings where you can, with good reliability, identify an etiology and direct therapy for the etiology without the heart catheterization.

Dr Vaidya: I agree with that. There’s another angle of this, too, where we are so commonly discussing how right heart catheterization is the “gold standard” in the diagnosis of PH. That’s only the case if it’s done accurately. The flip side is how commonly patients with true PAH or CTEPH or a predominantly PVR lesion have an underoccluded technical error when trying to get an accurate wedge pressure. It’s because their distal pulmonary arteries are larger in caliber, and this is a very common technical error that leads to an overestimated wedge pressure and missing the accurate diagnosis of PAH. It’s part of why it still takes 2½ years to make an accurate diagnosis.

That error can be vastly avoided if we are properly interpreting the echocardiogram in advance. Our fellows, for example, know that they are not to scrub in on a right heart catheterization with us until they’ve looked at the echocardiogram images themselves, so that if they underoclude a pulmonary capillary wedge tracing and the tracing blunts and it looks like it could be a venous wedge waveform but it’s 28 mm Hg when the patient echocardiogram has severe septal flattening, an E/e’ of 7, a small left artery, and an RVOT notch, then they know that they’ve probably underocluded, and they have to pay more careful attention technically in the catheterization lab.

The echocardiogram can be very helpful both ways to ensure that the right heart catheterization is also providing hemodynamic data that’s most consistent with the patient’s true overall clinical presentation.

Dr Edelman: All echocardiograms are not alike. All right heart catheterizations...
are not alike. When you get information that doesn’t fit, sometimes you need to step back and look at where the potential for error is. Some of these studies are being done at centers with different focuses or experience. PH centers can play a role in integrating and further reviewing the quality as well as obtaining more nuanced information from these studies.

Dr Farber: Just one last point about all that: the other part of this is that the echocardiogram is not near 100% accurate in diagnosing or suggesting diastolic heart disease. That’s one issue; the second aspect is that there are people who have every risk factor for diastolic heart disease and have true precapillary PAH. So I don’t know how, at least currently, you’re going to get away from right heart catheterizations, nor should you.

Dr Hassoun: I’ll say something about our experience, which is quite skewed at Hopkins, because we’re a PH center, and patients come in with a suspicion of PH. They’ve had several echocardiograms or other tests. We always start with the chest x-ray, V/Q scan, and CT scan with pulmonary angiogram (CTPA) to exclude either lung disease or thromboembolic disease. V/Q scan is a must for all our patients.

I agree with all that’s been said about echocardiograms in terms of the usefulness in ruling out valvular disease, diastolic dysfunction, left heart disease, etc. It’s extremely helpful. I agree with the comments made by Anjali about the RV systolic pressure, and this is the thing that I pay least attention to. I look at RV morphology, volume, septal displacement. We do TAPSE on all our patients, not only to assess RV proper function, but also for risk stratification.

We also use TAPSE for follow up. We decide based on the echocardiogram whether it’s left heart disease or more likely right heart disease, and that will lead us to eventually do a cardiac catheterization. To give you an example, if I have a middle-aged obese patient who has some systemic hypertension, an RV systolic pressure of 50, but a normal RV volume, I would be tempted to get a sleep study first and treat for 6 months in case a sleep disorder is confirmed before repeating the echocardiogram and deciding on further action.

We eventually perform right heart catheterization on all patients with a PH suspicion. This comes after a set of baseline tests that will lead us to place the patient in 1 of the 5 groups of World Symposium on Pulmonary Hypertension (WSPH) classification of PH. I am saying our experience is skewed because these patients come in with a suspected diagnosis of PH, and the challenge then becomes to decide whether this patient fits mainly in Group 1, Group 2, Group 3, Group 4, or Group 5. This will be very important before doing a right heart catheterization and considering treatment.

In addition, we use the echocardiogram for risk stratification, and if you look at the REVEAL score or the European Society of Cardiology/European Respiratory Society (ESC/ERS) recommendations, unfortunately, there is only pericardial effusion considered in the REVEAL score, and pericardial effusion and right arterial area for the so-called ESC/ERS traffic light table. I think more echocardiogram findings like TAPSE, fractional area change, or degree of tricuspid regurgitation should be used for stratification.

Finally, we use the echocardiogram for follow up after initiation of treatment, mainly focusing on TAPSE, fractional area change, to see if there are changes of function of the RV chamber. We haven’t talked about cardiac magnetic resonance imaging (MRI). We do cardiac MRI mainly for research purposes, but this is a modality that can be extremely important, at least for PAH in terms of assessing, again, RV function, such as RV ejection fraction, which has been shown to correlate with survival. There are so many other useful parameters that you can get with cardiac MRI.

Dr Vaidya: I would agree with that comment regarding the guidelines table. I’ve always thought it’s unfortunate that they only include right atrial area and pericardial effusion because that is a little limiting in broad utility, and there are data to support TAPSE and fractional area change and other features.

I think of it as overall echo markers of right heart performance. I completely agree that pericardial effusion and right atrial area should not be the only things included in that category.

Dr Leary: I don’t disagree with either of those comments, but from a logistical standpoint, what I think that the existing risk scores show us is that where we are right now in PH, we certainly don’t have a single magical imaging variable that prognosticates for our patients. So we’re left with old-school scales of justice, where we stack data on one side or the other to try and get a sense of whether our patient really is in a low-, intermediate-, or high-risk category. I think that we can broadly agree that imaging markers of the RV, whatever your favorite may be, are an important part of that risk assessment. The degree of derangement in a single marker may outweigh votes in a bunch of other categories, but any given marker rarely stands alone. What I heard from Paul and Anjali is that we have a lot of good markers out there. People have done good work correlating these to disease progression. What can be challenging with the plethora of high-dimensional data is deciding how to weight these things in clinical practice and coming up with a framework to put that into.

I don’t envy the people who created the risk scores for that reason . . . to try and make something that’s manageable, incorporating all these various inputs, all of which are somewhat colinear and hopefully are telling you similar things. Ultimately, though, I still think that you do want to look holistically at this and not get too married to any individual marker.

Dr Hassoun: I agree with you, Peter. I was complaining about the fact that, whether the REVEAL or the ESC/ERS risk scores, they have a couple of elements of echocardiograms. There are many biomarkers that have been associated with survival. I agree with you that we need to have a more holistic approach. If you look at the work that was done in the Swedish, in the German, and in the French registries using
the ESC/ERS risk stratification, they’ve looked at between 4 and 8 variables: hemodynamics, a little bit of echocardiogram, function, hemodynamics, etc. I think we need to have a number of imaging parameters to incorporate into our stratification scores.

MRI is not even mentioned in any of these. I think obtaining MRI may be more complicated from an availability standpoint, but I think it gives you so much more accurate information on both the left and the right heart and coupling between the right ventricle and the pulmonary artery and so many other things such as myocardial perfusion reserve by cardiac MRI, which we find correlates with survival. That means that there are so many things that have not been explored from an imaging standpoint.

Dr Edelman: I think we should talk about the role and potential role of MRI. I want to save that for just a little bit later. I’m still sticking to routine tests. I want to come back and talk a little bit about CT and V/Q scanning and their current roles and limitations because I think that, a lot of times, we are seeing patients who come in with dyspnea and often one of the first tests that’s ordered is a CT, particularly CT angiogram, to look for acute pulmonary embolism. On many of these studies, there’s no pulmonary embolism, but there are findings of PH such as pulmonary artery enlargement.

There is a lot of information that often isn’t looked at. You can get fairly good assessments of some of the cardiac structures as well and get some further ideas as to what may be contributing if there is PH present, including information regarding underlying lung disease.

Dr Leary: As with any imaging test, I think it’s hugely important where it’s being used. There is a ton of information on a CT scan, and I’m going to focus in on CTEPH for a second. If you put a CTPA in the hands of a chest radiologist, particularly one who’s focused on CTEPH or at a CTEPH center—even without a V/Q scan, they reliably identify the features of CTEPH that make the diagnosis likely based on the CT alone.

In this scenario, I think CTPA really does tell you a ton.

On the other hand, we also know that CT reads from someone who is not focused on CTEPH can frequently miss the features of the disease on CT. In this context, something like a V/Q scan is necessary to really draw attention to the perfusion fall out. I don’t think that we have moved beyond the era of V/Q scanning PH patients, mostly because of these differences in expertise or focus in terms of who’s reading the scan. While the technology is sound, I think greater expertise and focus than is widely available is necessary to really pull out a lot of the features that are important on a CTPA as they relate to PH in routine practice.

Dr Edelman: Peter, just like you said before about echocardiogram, I think the point is that there’s a richness, to use your words, in CT imaging as well that isn’t always readily tapped into at every location.

Dr Leary: Yes, that sounds right.

Dr Vaidya: I agree completely with the comments about CTPA and its use in CTEPH. That is certainly our experience at Temple, where the outside scans are sometimes not recognizing the findings that are truly, clinically obvious in our interpretations, but what a difference it makes, based on a center’s volume and experience in recognizing the disease state. I agree that the V/Q needs to remain part of the algorithm for the general clinician workup out there.

Dr Freed: I agree, too, that the V/Q needs to remain part of the algorithm. I think there are technological changes coming down the pipeline with CT, like dual-energy CT, that might be able to help in giving both anatomical and perfusion information. It’s not there yet, and it’s certainly not ubiquitous by any stretch, but I think that, as technology improves, we might be able to get our information out of one imaging modality rather than multiple ones, but certainly in total agreement that V/Q scan is still a major part of this workup.

Dr Pipavath: I don’t do nuclear medicine, so do you typically use V/Q scan as a rule-in modality or a rule-out modality? You are probably not, just on the basis of perfusion defects alone, suggesting CTEPH and starting to treat it. You would require a morphologic correlate, wouldn’t you say that?

Dr Vaidya: Correct.

Dr Pipavath: You will move onto CT angiogram in someone who has a slightly higher pretest probability at that point and then look more carefully to make sure that there is or there is no physical occlusion or a linear filling defect or a peripheral filling defect indicating CTEPH.

Dr Vaidya: That’s correct. The V/Q scan is very sensitive, but not specific, and so the CT angiogram is critical to then rule out other mimickers of CTEPH and to further characterize the location and nature of thromboembolic disease.

Dr Pipavath: What do you do when the V/Q scan is positive but there is no physical correlate? Do you just assume that it is because of Group 1 disease by excluding everything else?

Dr Vaidya: It can be that the description of a V/Q scan being positive in that context needs to again be interpreted by a CTEPH center because sometimes even the interpretation of the V/Q scans can be more complex than realized, and they can be read as false positive sometimes as well.

Dr Freed: Yes, and then there are diseases like sarcoma or vasculitis or pulmonary veno-occlusive disease or fibrosing mediastinitis. All of those can be false positives on a V/Q scan.

Dr Edelman: I think the value of the V/Q scan in this assessment, as Anjali said before, is really more of its negative predictive value. That really takes CTEPH off your list, and that’s why it stays in the algorithm. It’s readily available. It’s got very defined interpretation guidelines as opposed to what we heard about CT, where CT at the right place,
in the right hands, read by the right person, may approach that kind of operating characteristic of V/Q, but I had to add a lot of caveats to get there.

**Dr Leary:** I said that CT was rich, and I don’t back away from that statement. That’s not to say that I think we’ve climbed the mountain and are at the top. I think that, particularly as we’ve delved further and further into balloon pulmonary angioplasty and are working on chronic total occlusions and distal disease, what we’re finding is that we’re bumping into the limitations of a CTPA to really define anatomical disease in a way that’s as good as we want it to be, as we start targeting smaller vessels and taking different approaches to treat the disease.

Maybe dual-energy or some of these other approaches will get us there. Maybe they won’t, but I think there is still room for improvement in imaging around this space.

**Dr Farber:** To summarize, part of the problem is there are none of these imaging techniques that are specific enough to avoid any of the others. If you’re going to evaluate somebody for CTEPH, there are multiple different imaging techniques that are used so the surgeons or those doing balloon pulmonary angioplasty have an idea of what they will encounter.

**Dr Edelman:** I think we should probably spend some time discussing studies that are perhaps not as routinely used, such as cardiac MRI in evaluating PH.

**Dr Freed:** I think this was mentioned earlier, but one of the bread-and-butter kinds of things that MRI does is give you accurate RV volumes, RV ejection fraction, and RV mass. You don’t need contrast for it, it doesn’t take long to get it, and there’s no radiation involved. That alone, just giving you that type of information, is huge and really overcomes the limitations of echocardiography because it’s a 3-dimensional imaging modality. You can get a more global assessment of RV function, and this is what really helps to prognosticate in these patients.

That’s just the basic stuff that MRI can do, not to mention all the other sequences like tissue characterization that could potentially be helpful.

**Dr Leary:** As a physiologist and somebody who enjoys the idea of thinking about the RV an awful lot, I love MRI. Despite that fact, I use MRI almost not at all in my clinical practice outside of our research studies.

Within the setting of a multipronged risk stratification approach where we’re looking at B-type natriuretic peptide and 6-minute walk and some form of RV imaging, I’ve yet to be convinced that clinically a cardiac MRI has risen to that level where the juice is worth the squeeze, so to speak. Our patients tend to like echocardiography better; it is more accessible and is less costly to the system. I am just not sure that, in a multipronged risk stratification approach, use of cardiac MRI over echocardiogram moves the needle on prognostication. I love it as somebody who likes thinking about the RV, but I will say that clinically I don’t actually use it all that much.

**Dr Pipavath:** What do you think are its limitations? I don’t do cardiac MRI. My colleagues do it here. Those who do cardiac MRI, they seem to claim that it is, as you said, much more reproducible, but what—is it just the expense and the patient going into the magnet? Some of my colleagues have said that the expense tends to be very similar sometimes, but obviously the mean might be different at different locations. Is it just the expense, or is it that enough data have not been produced to comment on it?

**Dr Leary:** I’d say, for us, partially it’s the expense and partially just my bias. At least our long-term patients have grown up on echocardiograms, and so MRI feels intimidating. We’ve had a lot more pushback from patients after they get their MRI than after they get their echocardiogram. That’s just anecdotal experience, but it is fairly consistent anecdotal experience.

**Dr Freed:** I completely appreciate what you’re saying. I think that problems come when you’re at a center where potentially the echocardiograms are not read correctly, as we talked about before, or you simply have a lot of difficulty seeing the right ventricle for a variety of reasons. I think that’s when MRI might be particularly useful. I certainly don’t use it for every patient either, but there are still a number of cases where it could be helpful. I think this is also why, in the world of MRI, there’s a push to try to find other indications for MRI in this patient population that will make it worthwhile to go ahead and get that test, things that MRI can provide that echocardiography can’t and are useful in the management of these patients. I don’t know if we’re quite there yet, but there are a number of techniques being studied for this reason.

**Dr Edelman:** Can you elaborate on that a little more? I think your article in this issue talks quite a bit about RV strain.

**Dr Freed:** Yes. We talk about RV strain both for echocardiography and MRI. There’s a lot of literature out there on using RV strain with MRI, in a relatively easy way with no special sequence that you need to use ahead of time. In addition, there is 4-dimensional flow and T1 mapping, which provide data on flow dynamics and diffuse fibrosis, respectively. I think it’s still in its infancy in terms of what we can use it for in PH. There are studies out there showing that identifying diffuse fibrosis either in the septum or potentially in the RV free wall can be helpful in figuring out prognosis, for instance.

**Dr Edelman:** Another information source that may lead to PH identification are MRIs that might be obtained for evaluation of left ventricular issues and then come back with findings that then trigger a PH evaluation.

**Dr Freed:** Yes. MRIs can provide information similar to echocardiograms in terms of helping you with where exactly the PH is coming from, but it probably goes beyond echocardiography, too. For instance, MRI can help identify both intra- and extracardiac shunts, which 2-dimensional echocardiography might not be able to visualize. I agree MRI can also help in differentiating the
mechanisms or where the PH is actually coming from.

**Dr Edelman:** We’re getting close to the end of our hour here. I think we’ve covered most of what we had hoped to cover, but also want to give the opportunity for general comments or other things that people feel we may have missed and would like to add in here.

**Dr Leary:** We haven’t even talked about positron emission tomography! I must say, it’s a cool idea. As we move forward in imaging, thinking about trying to understand stress at the cellular level is an idea that’s out there and has some data behind it. It is certainly not ready for primetime clinically, but I think that, at the end of the day, we are trying to understand the myocyte under stress in the setting of increased afterload. I think we use morphology and strain and function as surrogates of that cellular stress, and I wonder if, in the future, we’ll be looking at biomarkers that are more focused in on the myocyte under strain. It’s kind of pie-in-the-sky stuff, but interesting to think about.

**Dr Edelman:** There is great potential for these studies to enhance our understanding of disease pathophysiology as well. I think that’s really where we would be going with MRI and positron emission tomography and studies that aren’t currently routinely used in clinical PH evaluation. I think we have reached the end of our hour, and I want to thank everyone for your input and participation. It’s been a great discussion.
Radiographic Signs and Patterns of Pulmonary Hypertension: A Pictorial Essay

Section Editor
Sean M. Studer, MD, MSc, FCCP

Hugo Carmona, MD
Department of Medicine
University of Washington
Seattle, WA

Wei Wu, MD
Department of Radiology
University of Washington
Seattle, WA

Sudhakar N.J. Pipavath, MD
Department of Radiology
University of Washington
Seattle, WA

INTRODUCTION
Pulmonary hypertension (PH) is a disease characterized by elevated mean pulmonary arterial pressure and/or elevated pulmonary vascular resistance, as measured by right heart catheterization. Individuals often present with dyspnea and decreased functional exertion. Imaging features of PH may be present prior to clinical diagnosis. Certain radiographic signs can be useful in identifying the etiology of the PH. We present a variety of imaging features that are aimed at making these etiologies apparent to clinicians, with a focus on those etiologies that do not otherwise usually have distinguishing clinical manifestations.

EVIDENCE OF PH ON PLAIN CHEST RADIOGRAPHY
There are a variety of signs that are present in advanced PH regardless of etiology. The most obvious begin with the changes in the main pulmonary artery (PA) itself. On plain radiography, enlargement of the main PA typically obscures the expected concavity between the aortic arch and the main PA silhouette, the so-called “aortopulmonary window” (Figure 1). Additionally, dilated descending left and right PAs can suggest PH (Figures 2 and 3). Right atrial enlargement and right ventricle (RV) enlargement (Figure 2) may also be evident.

Figure 1: Frontal chest radiograph of a 25-year-old woman with Group 1 pulmonary arterial hypertension secondary to systemic lupus erythematosus demonstrating loss of the aortopulmonary window (thick black arrow), now replaced by an outward convexity, due to main pulmonary artery enlargement. Additionally, the individual has bilateral dilated descending pulmonary arteries (thin black arrow [right] and white arrow [left]).

Figure 2: Lateral chest radiograph of a 33-year-old woman with pulmonary arterial hypertension and plexogenic arteriopathy demonstrating right ventricular enlargement as evidenced by obscuration of the expected retrosternal clear space (white arrow).
EVIDENCE OF PH ON CT

The main PA diameter (mPAD) should be measured on computed tomography (CT) 1 cm from the bifurcation of the right and left PAs, or at least at the widest portion within 3 cm of the bifurcation (Figure 4). An mPAD ≥ 29 mm has a sensitivity of 87%, specificity of 89%, and positive predictive value (PPV) of 0.97 for PH. Another common measurement compares mPAD to aorta diameter, abbreviated here as PA-Ao ratio. A PA-Ao ratio > 1 has a sensitivity of 57% and a specificity of 81% for PH. While mPAD dilation can suggest the presence of PH, it does not correlate with PH severity, but rather to the length of time that PH has been present.

In addition to static measurements of the great vessels, Scelsi et al. have shown that being able to visualize the main PA at the same level as the most caudal aspect of the aortic arch, the so called “egg-and-banana” sign (Figure 5), is also associated with the presence of PH. Particularly, they noted that its presence had a similar PPV (85%) to the PA-Ao ratio > 1 (PPV 87%) and that the combination increased the PPV to 90%.

Left ventricle (LV) and RV characteristics can also point to the presence of PH (Figure 6). An RV free wall thick-
Figure 5: Computed tomographic angiogram of the chest at the level of the caudal aspect of the aortic arch (yellow) in a 32-year-old man with Wiskott-Aldrich syndrome complicated with pulmonary hypertension. Note that the main pulmonary artery (pink) is visible at this level, the so called “egg-and-banana” sign.

Figure 6: Computed tomography of the chest with contrast, demonstrating an increased right ventricle-to-left ventricle ratio, as well as interventricular septal flattening (black arrow) in an individual with pulmonary hypertension, suggesting right ventricular pressure overload.
ness $\geq 6$ mm on CT has an odds ratio (OR) of 30.5 for PH, and an RV-to-LV luminal diameter ratio of $\geq 1.28$ carries an OR of 28.8. Interventricular septal flattening and reflux of contrast material down the inferior vena cava also suggest RV pressure overload (Figure 7).

**ETIOLOGIES OF PH**

While many of the above findings may still be nonspecific to PH, if PH is strongly suspected or confirmed clinically, the following findings might provide strong clues as to the etiology of the PH. There are a few diseases that have very distinct imaging findings and usually have little extrapulmonary clinical manifestations. We have decided to group these findings in order by the proposed World Symposium on Pulmonary Hypertension clinical group classifications for PH.

**Group 1**

This group is made up of a diverse set of precapillary and postcapillary diseases that lead to pulmonary arterial hypertrophy.

---

**Figure 7:** Computed tomographic angiogram of the chest demonstrating reflux at the level of the inferior vena cava (IVC; black arrow) due to elevated pulmonary artery pressures and elevated pulmonary vascular resistance.

**Figure 8:** Computed tomographic angiogram of the chest in a 33-year-old woman with pulmonary arterial hypertension and plexogenic arteriopathy. Images show tortuous, corkscrewlike peripheral pulmonary arteries (black arrow) and faint centrilobular nodules (thin black lines).
Plexogenic pulmonary arteriopathy is the pathognomonic histopathologic lesion of PAH,\textsuperscript{13} with its presence signifying the ongoing angiogenic pathology of PAH.\textsuperscript{14} The pulmonary vasculature undergoes a progression of changes from arterial medial hypertrophy to subsequent intimal proliferation and eventually compensatory plexus.\textsuperscript{15} Tortuous hypertrophic arterioles may be seen peripherally as a result (Figure 8).\textsuperscript{16} Poorly defined ground glass attenuation centrilobular nodules can be seen on CT (Figure 9), which might represent either the plexogenic lesions or cholesterol deposits.\textsuperscript{17}

Partial anomalous pulmonary venous return (PAPVR) is an anomalous venous connection in which some pulmonary venous return drains back to the right atrium, either via direct connection or through an atrial septal defect (ASD; Figure 10), but does not cause total cyanosis as might a total anomalous connection. Left-to-right shunting is present which might eventually lead to PH. PAPVR is overall a rare finding,\textsuperscript{18} but its presence should prompt search for ASD, especially a sinus venous type of ASD if the location of PAPVR is in the right upper lobe (Figure 11), as these are highly associated.\textsuperscript{19}

Pulmonary veno-occlusive disease (PVOD) is a postcapillary disease with
characteristic findings of interlobular septal thickening, resembling the parenchymal imaging findings of left-sided heart failure without clinical evidence of left-sided congestion (Figure 12).

Pulmonary capillary hemangiomatosis (PCH) may be on the spectrum with PVOD as one disease. PCH tends to present with diffuse, random ground glass attenuation nodules (Figure 13) corresponding to foci of capillary proliferation in the secondary pulmonary lobules. Characteristically, PCH is a postcapillary contributor to PH, as is PVOD. Notably, PCH and PVOD do not respond to pulmonary vasodilators, and there is an increase in risk of pulmonary edema and respiratory failure with these advanced vasodilator therapies.

Figure 11: T2 black blood sequence in the same individual as in Figure 10 confirms the presence of a sinus venosus type of atrial-septal defect (white arrow). Right atrium (RA), left atrium (LA), aorta (A), right ventricle (RV), and left ventricle (LV) are labeled on this image.

Figure 12: 42-year-old woman with pulmonary veno-occlusive disease (PVOD). Computed tomography of the chest demonstrating interlobular septal thickening (thin black arrow) and mediastinal and hilar lymphadenopathy (thick black arrow). These features are common to both PVOD and left-sided heart failure.

Figure 13: 17-year-old man with pulmonary capillary hemangiomatosis (PCH). Computed tomography of the chest demonstrates multiple randomly distributed ground glass attenuation nodules characteristic of PCH.
**Group 2**  
Chest radiography can show LV hypertrophy, as well as left atrial and ventricular dilation, all to suggest left-sided cardiomyopathy that is associated with Group 2 disease.

**Group 3**  
The main causes of Group 3 disease are the chronic hypoxemic respiratory diseases such as interstitial lung disease (ILD) and chronic obstructive pulmonary disease.\(^1\) The role for chest CT in making a noninvasive diagnosis for this group of diseases, particularly ILD, is well established.\(^2\)

**Group 4**  
Chronic thromboembolic PH (CTEPH) is an underdiagnosed etiology and is often diagnosed at the same time that an individual presents with manifestations of their PH.\(^3\) The diagnosis is increasingly important given advances in treatment.\(^4\)–\(^6\) CTEPH has several characteristic imaging features, including imaging findings of acute and chronic PA thrombi (Figures 14–16), bronchial artery hypertrophy (Figures 17 and 18), and mosaic attenuation (Figures 19–21).

**Group 5**  
Group 5 etiologies represent a variety of diseases for which the mechanism in association with PH is not yet well understood. These include sarcoidosis and hematologic malignancies, among others.

---

**Figure 14:** 26-year-old woman with chronic thromboembolic pulmonary hypertension. Computed tomographic angiogram of the chest shows an acute pulmonary embolism (arrow) in the right main pulmonary artery, seen as a central near-completely occlusive filling defect.

**Figure 15:** 26-year-old woman with chronic thromboembolic pulmonary hypertension (same individual as in Figure 14). Computed tomographic angiogram of the chest shows an acute pulmonary embolism in the right main pulmonary artery, seen as a central near-completely occlusive filling defect, superimposed on chronic pulmonary embolism (arrow), seen as peripheral filling defects in the basal trunk of the right lower lobe artery.
Figure 16: 26-year-old woman with chronic thromboembolic pulmonary hypertension (same individual as in Figures 14 and 15). Computed tomographic angiogram of the chest shows an acute pulmonary embolism in the right main pulmonary artery, seen as a central near-completely occlusive filling defect, superimposed on chronic pulmonary embolism, seen as peripheral filling defects in the basal trunk of the right lower lobe artery as well as the right lateral and posterior basal (arrow) segmental arteries.

Figure 17: 57-year-old man with chronic thromboembolic pulmonary hypertension. Computed tomographic angiogram of the chest demonstrates bronchial artery hypertrophy (white arrows) and diminished peripheral lung vascularity.
Figure 18: Same individual as in Figure 17. Computed tomographic angiogram of the chest in coronal projection demonstrates pulmonary artery narrowing (white arrow).

Figure 19: 29-year-old man with chronic thromboembolic pulmonary hypertension (CTEPH). Computed tomography of the chest demonstrating mosaic attenuation in the left lower lobe (black arrow). In individuals with pulmonary hypertension, mosaic attenuation of the lung is most commonly seen in individuals with CTEPH.

Figure 20: Same individual as in Figure 19. Left panel: Computed tomographic angiogram of the chest demonstrates a chronic pulmonary embolism in the basal trunk of the left lower lobe lobar artery. Middle panel: Single photon emission computed tomography perfusion image shows decreased perfusion (white arrow) in the corresponding left lower lobe artery distribution. Right panel: Conventional pulmonary angiogram shows both occlusion of the left lower lobe pulmonary artery and corresponding loss of contrast enhancement (black arrow).
CONCLUSIONS
Awareness of early and late radiographic and cross-sectional imaging features of PH may be helpful in early and accurate diagnosis. In many conditions that cause PH, imaging alone may suggest a specific etiology.

References
19. Van Praagh S, Carrera ME, Sanders SP, Mayer JE, Van Praagh R. Sinus venous defects: unroofing of the right pulmonary veins—anatomic and echocardiographic findings and sur-

Figure 21: Dual-energy computed tomography (CT) with an iodine map (left panel) and corresponding CT angiogram (CTA) in mediastinal window (right panel) in a 68-year-old male with chronic thromboembolic pulmonary hypertension. Iodine map (left panel) demonstrates areas of normal perfusion seen as green, while diminished perfusion is denoted as blue. The areas of poor perfusion (blue) on the iodine map correspond to areas of diminished vascularity on the CTA image (arrow).


When a Clot Is Not a Clot: An Unusual Cause of Progressively Worsening Dyspnea in a Previously Healthy Woman

Section Editor
Deborah J. Levine, MD

Nicholas Fox, MD
Pulmonary, Critical Care and Sleep Medicine
Medical University of South Carolina
Charleston, SC

Victor Test, MD
Pulmonary Critical Care Medicine
Duke University Medical Center
Durham, NC

Vinod Jona, MD
Pulmonary and Critical Care
McLeod Health System
Florence, SC

Russell Harley, MD
Pulmonary, Critical Care and Sleep Medicine
Medical University of South Carolina
Charleston, SC

Rahul G. Argula, MD
Pulmonary, Critical Care and Sleep Medicine
Medical University of South Carolina
Charleston, SC

PRESENTATION
A 61-year-old Caucasian female presented with a 4-month history of dyspnea on exertion. She was previously healthy, worked out regularly, and had no prior tobacco exposure. Her symptoms were preceded by a sharp, inspiratory chest pain (left sided), which was initially intermittent and later became persistent. A few days into her symptom course, she developed exertional dyspnea. A contrasted high-resolution computed tomography (HRCT) scan of the chest ordered by her primary care provider showed minimal, peripheral-appearing upper lobe and right middle lobe ground-glass opacities without any evidence of pulmonary emboli (PE) (Figure 1). She was given a course of antibiotics, 20 mg of prednisone for 5 days, and referred to a pulmonologist. With this, her chest pain improved but her dyspnea persisted. At the pulmonary evaluation a few weeks later, she was noted to be significantly hypoxemic. She was started on supplemental oxygen therapy. Given her persistent symptoms, she received 3 different additional courses of oral antibiotic therapy for a possible “resistant” pneumonia to no avail. Given the lack of improvement in her symptoms, her prednisone dose was increased, and she was subsequently referred to our institution.

ASSESSMENT
On physical examination at the time of initial evaluation at our institution, the patient was afebrile with pulse oximetry revealing an oxygen saturation of 100% on 5 L/min of supplemental oxygen. Oral exam was notable for several telangiectasias on her hard palate. Cardiac and pulmonary exams were unremarkable with a normal sounding P2 and no murmurs. Jugular venous pulse was not elevated. Musculoskeletal exam was negative for muscle or joint tenderness. On skin exam, several telangiectasias were noted across her anterior chest wall. There was no evidence of sclerodactyly or digital ulceration. There was neither...

![Figure 1: Initial contrasted chest computed tomography with minimal, peripheral, ground-glass opacities. No evidence of acute pulmonary emboli.](image-url)
cyanosis nor edema at the peripheries of her extremities. Her neurologic exam was also unremarkable. Her pulmonary function tests were normal except for an isolated reduction in the diffusing capacity of the lungs for carbon monoxide (DLCO) (Table 1). Her 6-minute walk distance was reduced at 290 m with a significant oxygen desaturation to 92% on 4 L/min. Her initial laboratory workup demonstrated a normal complete blood cell count as well as normal renal and liver function panels, and her serum levels of cardiac biomarkers were within normal limits. Her electrocardiogram was unremarkable as was her chest x-ray. We then ordered a repeat contrasted HRCT scan of her chest which demonstrated a worsening of the previously described airspace opacities. Her imaging now showed increased prominence of the upper lobe ground-glass opacities, again without any evidence of acute PE. The airspace opacities were peripheral in position and appeared to have a vascular predilection, and some of the opacities had a nodular appearance to them (Figure 2). An echocardiogram demonstrated a preserved ejection fraction with normal left and right ventricular size and function. There were no signs of valvulopathy or pulmonary hypertension (PH).

MANAGEMENT AND MONITORING
Further workup was pursued with an extensive autoimmune panel, including a myositis antibody panel and a hypersensitivity antibody panel, all of which were negative. Her creatine kinase level was within normal limits. Eventually, she underwent a bronchoscopy with transbronchial biopsies, which were unremarkable. Broncho-alveolar lavage was noted to be lymphocyte predominant. Cytology was unremarkable and negative for fungal organisms and malignant cells. Cryptogenic organizing pneumonia was the initial diagnosis of exclusion and so she was started on therapy with high-dose prednisone (1 mg/kg) and concomitant pneumocystis prophylaxis with trimethoprim-sulfamethoxazole. With steroid therapy, her symptoms improved initially, and her oxygen requirement decreased to 3 L/min during rest. However, after 8 weeks on high-dose prednisone, she returned to the clinic with worsening dyspnea and hypoxemia.

Given her persistent symptoms, low DLCO, a vascular distribution of her airspace opacities, and severe hypoxemia, pulmonary vascular disease continued to remain a possibility. She then underwent a ventilation/perfusion (V/Q) scan that returned positive for bilateral unmatched wedge-shaped perfusion defects, suggestive of pulmonary thromboembolic disease (Figure 3). Pulmonary veno-occlusive disease (PVOD) was also entertained as a possibility given her profound hypoxemia. She was started on systemic anticoagulation with rivaroxaban. A subsequent evaluation with a hypercoagulable panel did not reveal any underlying thrombophilia. A right heart catheterization (RHC) was consistent with mild PH and an elevated pulmonary vascular resistance (Table 2). She was then referred to the nearest pulmonary thrombo-endarterectomy center where a fluoroscopic pulmonary angiogram was completed. Interestingly, her pulmonary angiogram did not show any filling defects in the pulmonary vascular tree. The venous phase of the angiogram also showed normal emptying, making this unlikely to be pulmonary thromboembolic disease or PVOD. Ultimately, without a clear diagnosis, we pursued an urgent video-assisted

---

**Table 1. Pertinent PFT Values (PFTs Notable for Reduction in DLCO)**

<table>
<thead>
<tr>
<th>PFT parameters</th>
<th>Predicted</th>
<th>Measured</th>
<th>% Predicted</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVC, L</td>
<td>2.88</td>
<td>3.23</td>
<td>112%</td>
</tr>
<tr>
<td>FEV1</td>
<td>2.22</td>
<td>2.50</td>
<td>113%</td>
</tr>
<tr>
<td>FEV/FVC, %</td>
<td></td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>TLC, L</td>
<td>4.20</td>
<td>4.89</td>
<td>116%</td>
</tr>
<tr>
<td>RV, L</td>
<td>1.58</td>
<td>1.66</td>
<td>105%</td>
</tr>
<tr>
<td>DLCO, mL/mm Hg per minute</td>
<td>16.6</td>
<td>9.3</td>
<td>56%</td>
</tr>
</tbody>
</table>

Abbreviations: PFT indicates pulmonary function test; DLCO, diffusing capacity of the lungs for carbon monoxide; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; TLC, total lung capacity measured using plethysmography; RV, residual volume.
Thoracoscopic surgery lung biopsy, which provided a definitive diagnosis.

**DISCUSSION AND CLINICAL REASONING**

Though there was no evidence by history or on exam of a systemic autoimmune process, we checked both autoimmune and myositis antibody panels. These panels returned negative as did a hypersensitivity pneumonitis antibody panel. Considering her unremarkable aero-allergen exposure history and that her pulmonary function tests demonstrated normal estimates of lung volume by spirometry and plethysmography, we felt reassured that an interstitial lung disease was unlikely. However, the isolated DLCO on her pulmonary function tests continued to keep occult pulmonary vascular disease on the list of differential diagnoses. With her degree of hypoxemia and noting the peripheral and vascular distribution of the pulmonary opacities, we pursued a V/Q scan to evaluate for any possible microvascular pulmonary thromboembolic disease. The identification of at least two mismatched segmental perfusion defects (perfusion defects noted in areas of the lung with normal ventilation) on planar imaging is considered “high probability” for PE by the Prospective Investigation of Pulmonary Embolism Diagnosis study’s criteria.\(^1\) In patients with suspected chronic thromboembolic PH (CTEPH), a V/Q scan is more “sensitive” as it can detect distal and subsegmental perfusion defects that can often be missed on contrast-enhanced chest CT imaging.\(^2\)

Progressive dyspnea on exertion, a decreased 6-minute walk distance, and an isolated low D\(_2\)CO in concert with a chest CT negative for acute PE should prompt consideration of pulmonary vascular disease. Chronic thromboembolic disease (CTED) and CTEPH are two causes of pulmonary vascular disease due to thromboembolic events. CTEPH can occur in 0.4% to 8.8% of patients who develop an acute PE.\(^3\) One-half of patients with CTEPH do not recall ever having had a diagnosis of PE.\(^4\) A diagnosis of CTEPH becomes obvious typically following 6 months after the index PE event. CTED is diagnosed in patients who have imaging evidence of embolic burden in the pulmonary vasculature but do not have RHC-documented PH.\(^5\) Both CTEPH and CTED are diagnosed by means of a V/Q scan and can reportedly be associated with normal-appearing pulmonary arteries on contrasted chest CT imaging in a significant number of patients. Our patient’s V/Q scan was positive for multiple perfusion defects (Figure 3) but contrasted CT imaging did not reveal any filling defects in the pulmonary arteries. An RHC is also important for the diagnosis of CTEPH. Despite this patient’s echocardiogram being normal, an RHC was pursued (Table 2). This was followed by a dedicated fluoroscopic pulmonary angiogram to determine the pulmonary vascular thrombotic burden contributing to her PH. The findings of mildly elevated pulmonary pressures, moderately elevated pulmonary vascular resistance, and the absence of a significant clot burden on pulmonary angiography were inconsistent with a diagnosis of significant CTEPH. Her pulmonary hemodynamics and unremarkable venous-phase emptying noted on the pulmonary angiogram were also inconsistent with PVOD, another diagnosis which was considered.\(^6\)

While the diagnosis remained elusive, the patient continued to have a functional decline with increasing oxygen requirement. As her clinical picture remained concerning for a pulmonary vascular disease, we revised our list of differential diagnoses to include atypical vasculitis, an embolic or malignant phenomenon, and although less likely, we left PVOD on the differential. Considering that there was no evidence of an infectious source by exam or blood work, septic PE was also considered an

---

**Figure 3:** Planar ventilation/perfusion (V/Q) scan images demonstrating bilateral unmatched, wedge-shaped perfusion defects.

**Table 2. Right Heart Catheterization**

<table>
<thead>
<tr>
<th>RHC variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAP</td>
<td>4 mm Hg</td>
</tr>
<tr>
<td>RVP</td>
<td>41/2 mm Hg</td>
</tr>
<tr>
<td>PAP</td>
<td>42/18 mm Hg</td>
</tr>
<tr>
<td>mPAP</td>
<td>27 mm Hg</td>
</tr>
<tr>
<td>PCWP</td>
<td>6 mm Hg</td>
</tr>
<tr>
<td>CO (Fick)</td>
<td>4.2 L/min</td>
</tr>
<tr>
<td>CI</td>
<td>2.8 L/min per m(^2)</td>
</tr>
<tr>
<td>PVR</td>
<td>5.0 Wood units</td>
</tr>
<tr>
<td>SaO(_2) sat</td>
<td>94.7%</td>
</tr>
<tr>
<td>PAO(_2) sat</td>
<td>70.4%</td>
</tr>
</tbody>
</table>

Abbreviations: RHC indicates right heart catheterization; RAP, right atrial pressure; RVP, right ventricular pressure; PAP, pulmonary arterial pressure; mPAP, mean pulmonary arterial pressure; PCWP, pulmonary capillary edge pressure; CO, cardiac output as measured by Fick equation; CI, cardiac index; PVR, pulmonary vascular resistance; SaO\(_2\) sat, systemic oxygen saturation; PAO\(_2\) sat, pulmonary artery oxygen saturation.
unlikely diagnosis. As previously mentioned, there was no serologic evidence supporting the diagnosis of a rheumatologic disorder or pulmonary vasculitis. Other conditions that may result in pulmonary perfusion abnormalities and had previously been described in the extant literature included fat emboli, pulmonary capillary hemangiomatosis, pulmonary vasculitis, and pulmonary tumor emboli.7

Ultimately, the patient underwent a surgical lung biopsy via video-assisted thoracoscopic surgery to get a definitive diagnosis. The pathology was consistent with a primary pulmonary intravascular large B-cell lymphoma (IVLBCL) (Figure 4).

Pulmonary IVLBCL is an extremely rare type of extranodal large B-cell lymphoma first described by Pfleger and Tappeiner in 1958.9 This disease is characterized by a distinct proliferation of lymphomatous cells within the pulmonary microvasculature. Clinical symptoms and signs result from a compromised blood flow in the pulmonary capillaries. Pulmonary capillaries are particularly vulnerable while larger arteries and veins are typically spared, resulting in a significant gas exchange derangement. While lung involvement is common, it is rare for the primary presentation to be isolated to the lungs. Common presenting features include fever, weight loss, and anemia; however, the presentation varies depending on the organ(s) affected.9 With regard to primary pulmonary disease, dyspnea, cough, and hypoxemia are the most notable symptoms. The CT findings are variable but include ground-glass opacities, centrilobular nodules, and interlobular septal thickening. Tissue biopsy by transbronchial biopsy or surgical lung biopsy remains the “gold standard” for diagnosis. The prognosis for this aggressive lymphoma is typically poor, often due in part to a delay in diagnosis.10

Unfortunately, in a significant number of cases the diagnosis is often arrived at by autopsy. For our patient, the persistent and systematic pursuit of a diagnosis despite conflicting data (positive V/Q scan in absence of discernable risk factors for venous thromboembolism) helped us arrive at this diagnosis in a timely fashion. She received 6 cycles of a chemotherapy regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone under the supervision of a malignant-hematology specialist. She responded very well and was weaned off supplemental oxygen quickly following a remission of her disease. Currently, she is over 18 months from her last chemotherapy dose. She reported no physical limitations at her last evaluation. Her lymphoma remains in remission.

CONCLUSION
Primary pulmonary IVLBCL.

Teaching Points

1. A V/Q scan is sensitive for detecting perfusion defects in both PE and CTEPH.
2. A contrast-enhanced CT scan of the chest can be falsely negative in up to 49% of patients with CTEPH.
3. The differential diagnosis for perfusion defects on V/Q scan includes CTEPH, pulmonary vasculitis, pulmonary capillary hemangiomatosis, tumor emboli, and fat emboli.
4. Primary pulmonary IVLBCL is a rare type of B-cell lymphoma. It is characterized by proliferation of lymphomatous cells within the pulmonary microvasculature.
5. Primary pulmonary IVLBCL is a rare condition that can mimic CTEPH due to the tumoral cell occlusion of the pulmonary microvasculature. Lung biopsy is the only definitive way of diagnosis. Early diagnosis can result in a potential remission.

References


Figure 4: Pulmonary artery, with intimal proliferation and intraluminal lymphoma cells. The lumen is severely narrowed due to the lymphomatous cell burden in the vessel.


Facilitating and Improving Adherence: The Development of a Pulmonary Arterial Hypertension Self-Care Management Agreement

Successful disease management includes improvement in a patient’s quality of life, particularly when working with patients suffering from pulmonary arterial hypertension (PAH). This success is achieved through a team approach between patients, families, and their health care providers. Providers often prescribe treatment regimens and offer recommendations to slow disease progression and allow patients to become more functional. Adherence to these regimens is critical to the patients’ overall morbidity and mortality. Failure to adhere to the recommendations set forth by health care providers often leads to clinical worsening and increased health care costs. We will briefly examine the issue of medication nonadherence and how the development of a self-care responsibilities agreement changed the practice of one pulmonary hypertension (PH) center for the better.

The World Health Organization (WHO) defines medication adherence as “the degree to which the person’s behavior corresponds with the agreed recommendations from a health care provider.” Perhaps one of the greatest challenges health care providers face is the matter of patient nonadherence. The prevalence of medication nonadherence is astonishing: “In some disease conditions, more than 40% of patients sustain significant risks by misunderstanding, forgetting, or ignoring health care advice.” Medication nonadherence can range from never filling a prescription, to stopping medication without notifying the prescriber, to not taking a medication as prescribed, or by not following the recommendations associated with a prescribed medication. The overall outcome of such behavior has adverse consequences. These consequences include “waste of medication, disease progression, reduced functional abilities, a lower quality of life, and increased use of medical resources such as nursing homes, hospital visits, and hospital admissions.”

In the field of PAH, the consequences of medication nonadherence can be dangerous and often life threatening, particularly when working with parenteral prostacyclins. PAH medications are unique and complex and warrant a level of respect regarding their safety profiles. In our PH practice, various methods were employed in an effort to prevent nonadherence and improve patient outcomes. These methods included forming a personal connection and level of trust between patient and prescriber. Additionally, a substantial amount of time was spent educating on disease management and medication nuances. Despite these methods, nonadherence was present in our practice.

In an effort to address the issue of nonadherence, parenteral prostacyclin patients in our practice were observed over a 6-month period. These patients in particular were chosen because of the risks associated with nonadherence in this specific medication category. Patient interactions occurred during inpatient and outpatient encounters to substantiate evidence of adherence with particular safety measures discussed at length with patients during various training/education sessions. The results of this survey demonstrated gaps in what parenteral prostacyclin patients were taught, comprehended, and what was actually being practiced concerning medication safety. These results indicated that further measures were required to ensure medication adherence, safety, and overall patient wellness.

Our program initiated a thoughtful review of the literature to deepen our understanding of patient adherence and strategies that had the potential to change baseline behavior. Medical entities incorporating the use of contracts or agreements to increase medication adherence were investigated, particularly in the field of pain management. The research showed that the effectiveness of such documents regarding opioid use remained unclear. However, there is absolutely no research involving the use of such a document in the realm of medication adherence and PAH. Moreover, based on research involving opioid therapy, the use of the term “contract” was highly detested, as it “can be perceived as coercive, can erode physician–patient trust, and implies that failure to agree will result in loss of access.” It became clear that verbiage used in these kinds of documents could stigmatize patients. The language chosen could be implied as “mistrustful, accusatory, and even
confrontational.” Therefore, special care needed to be taken when writing such a document. The term “contract” would not be used for the development of an agreement for our PAH purposes.

Based on these research efforts, a PAH self-care responsibilities agreement was developed in order to increase adherence and hold patients and PH team members accountable for discussing and agreeing upon various measures to increase safety and overall health. It was decided among all members of the PH team that this self-care responsibilities agreement would be extended to include all PAH patients on drug therapy, not just parenteral prostacyclin patients as initially planned. It should be noted that a discussion occurred with the hospital legal department, who indicated this would not be a legally binding document.

Over the next 4 weeks, a self-care responsibilities agreement was drafted in collaboration with the PH team including physicians, nurses, and nurse practitioners. This agreement was narrowed to 14 key points deemed necessary for discussion once starting the treatment for PAH. These points ranged from understanding the diagnosis of PAH and the medications prescribed, to the risks of pregnancy and the use of contraception, to not stopping PAH therapies for any reason without discussing with the PH team. A sample of the agreement is included in the Appendix. Each patient was provided a copy of the agreement to read privately. Subsequently, time was allotted to provide further education, discuss benefits, and engage each patient in discussion regarding the points within the agreement. The patient was made aware that the agreement was not a legally binding document. They were then asked to sign the agreement along with a PH team member. This agreement was then scanned into the patient’s electronic medical record. By placing this agreement into the patient’s chart, it allowed the PH team access to the signed agreement in order to reexamine when necessary if the plan was not being followed or as a refresher for both the PH team and patient in the future.

Patients on all forms of medication therapy for the treatment of PAH were reassessed during inpatient visits and follow-up outpatient appointments for adherence, understanding, and recollection of the key points within the self-care responsibilities agreement. We did not formally score or track adherence issues before and after implementation of the self-care agreement. However, we believe that over the course of 1 year, the gap that had previously existed involving adherence with PAH medications and safety measures prior to the self-care responsibilities agreement had narrowed. Patients appeared more adherent to the safety measures and treatment plan set in place, especially those on parenteral prostacyclins. The level of education, discussion, and shared decision making between the patient and PH team, based on the self-care responsibilities agreement, generated an environment of respect that could ultimately lead to better patient outcomes.

Nonadherence to medication regimens and recommended treatment best practices is a serious challenge that patients and providers struggle with daily. Nonadherence leads to increased health care costs and an overall risk to a patient’s health and wellness. Patients with PAH are often prescribed medications and plans of care that, if not followed or administered properly, can have life-threatening consequences. In order to combat our issues with nonadherence, a PAH self-care responsibilities contract was developed and used with all patients on therapy for PAH. The overall outcome of developing and implementing the self-care agreement was positive for our program, which subsequently narrowed the knowledge gap that existed regarding the PAH plan of care. By narrowing the gap, we were able to combat our challenges with nonadherence and ultimately improve the success of our patients’ PAH treatment regimens.

References


SAMPLE COPY

Beaumont

Pulmonary Arterial Hypertension (PAH) Self Care Management Responsibilities and Plan

The effectiveness and safety of pulmonary arterial hypertension (PAH) management depends on a collaborative approach between the patient and the multidisciplinary team. My PAH management team has educated me in regards to the PAH disease process, classification, testing, and treatment in order for me to manage PAH daily.

I, ________________________, understand and agree that the following are my self care responsibilities as a patient of the Beaumont Pulmonary Hypertension Center:

1. I will notify the Pulmonary Hypertension Center in advance of any planned tests, procedures, or surgeries in order to receive instructions for care.

2. If I am on intravenous or subcutaneous drug therapy for pulmonary arterial hypertension, I agree to carry my back up medication, back up pump, and supplies with me at all times.

3. I agree to carry the emergency card provided by the Pulmonary Hypertension Center.

4. I agree to notify all other healthcare providers of my diagnosis of pulmonary arterial hypertension and any pulmonary arterial hypertension medications I am taking.

5. I agree to notify the Pulmonary Hypertension Center of any and all medications I take, including prescription medications, over the counter medications, vitamins, and herbal supplements.

6. If I am female, I understand the increased risk pregnancy places on myself and the unborn child. I understand that I must not become pregnant. I agree to utilize 2 forms of contraception or have an intrauterine device placed.

7. I agree to have laboratory testing completed as ordered by the PAH management team.

8. The risks of smoking have been explained to me. I agree to abstain from smoking cigarettes, pipes, cigars, or inhaling any substance into my lungs.

9. I agree to abstain from illicit drug use such as cocaine and methamphetamines.

10. I agree to follow a 2 gram sodium diet.

11. I have been instructed on the importance of using oxygen and agree to follow my written plan.

12. I agree to avoid NSAIDS (non-steroidal anti-inflammatory drugs like Motrin, Aleve, etc.) and nasal/oral decongestants containing pseudoephedrine.

13. I agree to take my PAH medications daily and will not stop taking the medications for any reason unless directly instructed to do so by my pulmonary hypertension physician.

14. I have been instructed on the risks and potential side effects of the pulmonary arterial hypertension medications.

I understand the above and agree to follow this plan

Signature ____________________________ Printed Name ____________________________

Witness ____________________________ Date ____________________________

Appendix: Sample Pulmonary Arterial Hypertension Self-Care Management Agreement.
Advances in Pulmonary Hypertension now available online only

Advances in Pulmonary Hypertension is now exclusively available at www.AdvancesinPH.org. Be sure that you have registered for a free account to receive each issue alert and Table of Contents right in your inbox! Additionally, the benefits of registering include:

• Ability to share articles easily with your peers around the globe.
• Creating a Favorites list down to the article level for those articles you frequently refer to.
• Viewing abstracts and exporting citations easily.